

# **OPDIVO<sup>®</sup> (Nivolumab)**

## **Injection Concentrate 10mg/mL**

### **1. NAME OF THE MEDICINAL PRODUCT**

OPDIVO 10 mg/mL concentrate for solution for infusion.

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each mL of concentrate contains 10 mg of nivolumab.

One vial of 4 mL contains 40 mg of nivolumab.

One vial of 10 mL contains 100 mg of nivolumab.

One vial of 12 mL contains 120 mg of nivolumab

Nivolumab is produced in Chinese hamster ovary cells by recombinant DNA technology.

#### Excipient with known effect

Each mL of concentrate contains 0.1 mmol (or 2.5 mg) sodium.

For the full list of excipients, see section 6.1.

### **3. PHARMACEUTICAL FORM**

Concentrate for solution for infusion (sterile concentrate).

Clear to opalescent, colorless to pale yellow liquid that may contain few light particles. The solution has a pH of approximately 6.0 and an osmolality of approximately 340 mOsm/kg.

### **4. CLINICAL PARTICULARS**

#### **4.1 Therapeutic indications**

##### Melanoma

OPDIVO as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.

##### Adjuvant treatment of melanoma

OPDIVO as monotherapy is indicated for the adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection (see section 5.1).

##### Non-Small Cell Lung Cancer (NSCLC)

OPDIVO is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on approved therapy for these aberrations prior to receiving OPDIVO.

##### Neoadjuvant treatment of NSCLC

OPDIVO, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors  $\geq 4$ cm or node positive) non-small cell lung cancer (NSCLC).

#### Neoadjuvant and adjuvant treatment of NSCLC

OPDIVO, in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by OPDIVO as monotherapy as adjuvant treatment, is indicated for the treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression  $\geq 1\%$  (see section 5.1 for selection criteria).

#### Renal Cell Carcinoma (RCC)

OPDIVO as monotherapy, is indicated for the treatment of adult patients with advanced or metastatic renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

OPDIVO in combination with cabozantinib (tablets) is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (see section 5.1).

#### Gastric, gastro-oesophageal junction (GEJ) or oesophageal adenocarcinoma

OPDIVO in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS)  $\geq 5$ .

#### Urothelial carcinoma

OPDIVO in combination with cisplatin and gemcitabine is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma.

## **4.2 Posology and method of administration**

Treatment must be initiated and supervised by physicians experienced in the treatment of cancer.

#### PD-L1 testing

If specified in the indication, patient selection for treatment with OPDIVO based on the tumour expression of PD-L1 should be assessed by a CE-marked in vitro IVD medical device test. If the CE-marked IVD is not available, an alternative validated test should be used (see sections 4.1, 4.4, and 5.1).

#### Posology

##### *OPDIVO as monotherapy*

The recommended dose of OPDIVO is 3 mg/kg administered intravenously over 30 minutes every 2 weeks.

##### *OPDIVO in combination with cabozantinib (tablets)*

##### *Renal cell carcinoma*

The recommended dose is nivolumab administered intravenously at either 240 mg every 2 weeks **or** 480 mg every 4 weeks in combination with 40 mg cabozantinib (tablets) administered orally every day.

**Table 1: Recommended doses and infusion times for intravenous administration of nivolumab in combination with oral administration of cabozantinib (tablets) for RCC**

	Combination phase
<b>Nivolumab</b>	240 mg every 2 weeks over 30 minutes or 480 mg every 4 weeks over 30 minutes
<b>Cabozantinib (tablets)</b>	40 mg once daily

*OPDIVO in combination with Chemotherapy*

*Gastric, gastro-oesophageal junction or oesophageal adenocarcinoma*

The recommended dose is 360 mg nivolumab administered intravenously over 30 minutes in combination with fluoropyrimidine- and platinum-based chemotherapy administered every 3 weeks or 240 mg nivolumab administered intravenously over 30 minutes in combination with fluoropyrimidine- and platinum-based chemotherapy administered every 2 weeks (see section 5.1). Treatment with nivolumab is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.

*Neoadjuvant treatment of non-small cell lung cancer*

The recommended dose is 360 mg nivolumab administered intravenously over 30 minutes in combination with platinum-based chemotherapy every 3 weeks for 3 cycles (see section 5.1).

*Neoadjuvant and adjuvant treatment of non-small cell lung cancer*

The recommended dose is 360 mg nivolumab administered intravenously over 30 minutes in combination with platinum-based chemotherapy every 3 weeks for 4 cycles in the neoadjuvant phase, followed by adjuvant treatment with nivolumab 480 mg as monotherapy every 4 weeks. Treatment is recommended until disease progression or recurrence, unacceptable toxicity, or up to 13 cycles (see section 5.1).

*First-line treatment of unresectable or metastatic urothelial carcinoma*

The recommended dose is 360 mg nivolumab administered intravenously over 30 minutes in combination with cisplatin and gemcitabine every 3 weeks for up to 6 cycles followed by nivolumab monotherapy administered intravenously at either 240 mg every 2 weeks over 30 minutes **or** at 480 mg every 4 weeks over 30 minutes (see section 5.1). Treatment with nivolumab is recommended until disease progression, unacceptable toxicity, or up to 24 months from first dose, whichever comes first.

*Duration of treatment*

Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient.

For adjuvant therapy, the maximum treatment duration with OPDIVO is 12 months.

For OPDIVO in combination with cabozantinib, OPDIVO should be continued until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression. Cabozantinib should be continued until disease progression or unacceptable toxicity. Refer to the package insert for cabozantinib.

Dose escalation or reduction is not recommended for OPDIVO as monotherapy or in combination with other therapeutic agents. Dosing delay or discontinuation may be required based on individual safety

and tolerability. Guidelines for permanent discontinuation or withholding of doses are described in Table 2. Detailed guidelines for the management of immune-related adverse reactions are described in section 4.4. When nivolumab is administered in combination with other therapeutic agents, refer to the package insert of these other combination therapeutic agents regarding dosing.

**Table 2: Recommended treatment modifications for OPDIVO or OPDIVO in combination**

<b>Immune-related adverse reaction</b>	<b>Severity</b>	<b>Treatment modification</b>
Immune-related pneumonitis	Grade 2 pneumonitis	Withhold dose(s) until symptoms resolve, radiographic abnormalities improve, and management with corticosteroids is complete
	Grade 3 or 4 pneumonitis	Permanently discontinue treatment
Immune-related colitis	Grade 2 or 3 diarrhoea or colitis	Withhold dose(s) until symptoms resolve and management with corticosteroids, if needed, is complete
	Grade 4 diarrhoea or colitis	Permanently discontinue treatment
Immune-related hepatitis	Grade 2 elevation in aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin	Withhold dose(s) until laboratory values return to baseline and management with corticosteroids, if needed, is complete
	Grade 3 or 4 elevation in AST, ALT, or total bilirubin	Permanently discontinue treatment
<b>NOTE:</b> for RCC patients treated with <b>OPDIVO in combination with cabozantinib</b> with liver enzyme elevations, see dosing guidelines following this table.		
Immune-related nephritis and renal dysfunction	Grade 2 or 3 creatinine elevation	Withhold dose(s) until creatinine returns to baseline and management with corticosteroids is complete
	Grade 4 creatinine elevation	Permanently discontinue treatment
Immune-related endocrinopathies	Symptomatic Grade 2 or 3 hypothyroidism, hyperthyroidism, hypophysitis	Withhold dose(s) until symptoms resolve and management with corticosteroids (if needed for symptoms of acute inflammation) is complete. Treatment should be continued in the presence of hormone replacement therapy <sup>a</sup> as long as no symptoms are present
	Grade 2 adrenal insufficiency	
	Grade 3 diabetes	
	Grade 4 hypothyroidism, hyperthyroidism, hypophysitis Grade 3 or 4 adrenal insufficiency Grade 4 diabetes	Permanently discontinue treatment
Immune-related skin adverse reactions	Grade 3 rash	Withhold dose(s) until symptoms resolve and management with corticosteroids is complete
	Grade 4 rash	Permanently discontinue treatment
	Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN)	Permanently discontinue treatment (see section 4.4)

**Table 2: Recommended treatment modifications for OPDIVO or OPDIVO in combination**

Immune-related myocarditis	Grade 2 myocarditis	Withhold dose(s) until symptoms resolve and management with corticosteroids is complete <sup>b</sup>
	Grade 3 or 4 myocarditis	Permanently discontinue treatment
Other immune-related adverse reactions	Grade 3 (first occurrence)	Withhold dose(s)
	Grade 4 or recurrent Grade 3; persistent Grade 2 or 3 despite treatment modification; inability to reduce corticosteroid dose to 10 mg prednisone or equivalent per day	Permanently discontinue treatment

Note: Toxicity grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v4).

<sup>a</sup> Recommendation for the use of hormone replacement therapy is provided in section 4.4.

<sup>b</sup> The safety of re-initiating nivolumab therapy in patients previously experiencing immune-related myocarditis is not known.

OPDIVO as monotherapy or in combination with other therapeutic agents should be permanently discontinued for:

- Grade 4 or recurrent Grade 3 adverse reactions;
- Persistent Grade 2 or 3 adverse reactions despite management.

When OPDIVO is administered in combination with chemotherapy, refer to the package insert of the other combination therapy agents regarding dosing. If any agents are withheld, the other agents may be continued. If dosing is resumed after a delay, either the combination treatment, OPDIVO monotherapy or chemotherapy alone could be resumed based on the evaluation of the individual patient.

#### *OPDIVO in combination with cabozantinib in RCC*

When OPDIVO is used in combination with cabozantinib, the above treatment modifications in Table 2 also apply to the OPDIVO component. In addition, for liver enzyme elevations, in patients with RCC being treated with OPDIVO in combination with cabozantinib:

- If ALT or AST > 3 times ULN but ≤ 10 times ULN without concurrent total bilirubin ≥ 2 times ULN, both OPDIVO and cabozantinib should be withheld until these adverse reactions recover to Grades 0-1. Corticosteroid therapy may be considered. Rechallenge with a single medicine or rechallenge with both medicines after recovery may be considered. If rechallenging with cabozantinib, refer to cabozantinib package insert.
- If ALT or AST > 10 times ULN or > 3 times ULN with concurrent total bilirubin ≥ 2 times ULN, both OPDIVO and cabozantinib should be permanently discontinued and corticosteroid therapy may be considered.

#### *Special populations*

##### *Paediatric population*

The safety and efficacy of OPDIVO in children below 18 years of age have not been established. No data are available.

##### *Elderly*

No dose adjustment is required for elderly patients (≥ 65 years) (see sections 5.1 and 5.2).

### *Renal impairment*

Based on the population pharmacokinetic (PK) results, no dose adjustment is required in patients with mild or moderate renal impairment (see section 5.2). Data from patients with severe renal impairment are too limited to draw conclusions on this population.

### *Hepatic impairment*

Based on the population PK results, no dose adjustment is required in patients with mild hepatic impairment (see section 5.2). Data from patients with moderate or severe hepatic impairment are too limited to draw conclusions on these populations. OPDIVO must be administered with caution in patients with moderate (total bilirubin  $> 1.5 \times$  to  $3 \times$  the upper limit of normal [ULN] and any AST) or severe (total bilirubin  $> 3 \times$  ULN and any AST) hepatic impairment.

### Method of administration

OPDIVO is for intravenous use only. It is to be administered as an intravenous infusion over a period of 30 minutes. The infusion must be administered through a sterile, non-pyrogenic, low protein binding in-line filter with a pore size of 0.2-1.2  $\mu\text{m}$ .

OPDIVO must not be administered as an intravenous push or bolus injection.

The total dose of OPDIVO required can be infused directly as a 10 mg/mL solution or can be diluted to as low as 1 mg/mL with sodium chloride 9 mg/mL (0.9%) solution for injection or glucose 50 mg/mL (5%) solution for injection.

When administered in combination with chemotherapy, OPDIVO should be given first followed by chemotherapy on the same day. Use separate infusion bags and filters for each infusion.

For instructions on the preparation and handling of the medicinal product before administration, see section 6.6.

## **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

## **4.4 Special warnings and precautions for use**

### Assessment of PD-L1 status

When assessing the PD-L1 status of the tumour, it is important that a well-validated and robust methodology is used.

Immune-related adverse reactions.

When nivolumab is administered in combination, refer to the package insert of the other combination therapy agents prior to initiation of treatment. Immune-related adverse reactions have occurred at similar frequencies when OPDIVO was administered in combination with cabozantinib relative to nivolumab monotherapy. Therefore, the guidance below for immune-related adverse reactions applies to the OPDIVO component of the combination, except where specifically noted. Most immune-related adverse reactions improved or resolved with appropriate management, including initiation of corticosteroids and treatment modifications (see section 4.2).

Immune-related adverse reactions affecting more than one body system can occur simultaneously.

Cardiac and pulmonary adverse reactions including pulmonary embolism have also been reported with combination therapy. Patients should be monitored for cardiac and pulmonary adverse reactions continuously, as well as for clinical signs, symptoms, and laboratory abnormalities indicative of electrolyte disturbances and dehydration prior to and periodically during treatment.

Patients should be monitored continuously (at least up to 5 months after the last dose) as an adverse reaction with nivolumab may occur at any time during or after discontinuation of nivolumab therapy.

For suspected immune related adverse reactions, adequate evaluation should be performed to confirm aetiology or exclude other causes. Based on the severity of the adverse reaction, nivolumab should be withheld and corticosteroids administered. If immunosuppression with corticosteroids is used to treat an adverse reaction, a taper of at least 1 month duration should be initiated upon improvement. Rapid tapering may lead to worsening or recurrence of the adverse reaction. Non-corticosteroid immunosuppressive therapy should be added if there is worsening or no improvement despite corticosteroid use.

Nivolumab should not be resumed while the patient is receiving immunosuppressive doses of corticosteroids or other immunosuppressive therapy. Prophylactic antibiotics should be used to prevent opportunistic infections in patients receiving immunosuppressive therapy.

Nivolumab must be permanently discontinued for any severe immune related adverse reaction that recurs and for any life threatening immune related adverse reaction.

#### Immune-related pneumonitis

Severe pneumonitis or interstitial lung disease, including fatal cases, has been observed with nivolumab treatment (see section 4.8). Patients should be monitored for signs and symptoms of pneumonitis such as radiographic changes (e.g., focal ground glass opacities, patchy infiltrates), dyspnoea, and hypoxia. Infectious and disease-related aetiologies should be ruled out.

For Grade 3 or 4 pneumonitis, nivolumab must be permanently discontinued, and corticosteroids should be initiated at a dose of 2 to 4 mg/kg/day methylprednisolone equivalents.

For Grade 2 (symptomatic) pneumonitis, nivolumab should be withheld and corticosteroids initiated at a dose of 1 mg/kg/day methylprednisolone equivalents. Upon improvement, nivolumab may be resumed after corticosteroid taper. If worsening or no improvement occurs despite initiation of corticosteroids, corticosteroid dose should be increased to 2 to 4 mg/kg/day methylprednisolone equivalents and nivolumab must be permanently discontinued.

#### Immune-related colitis

Severe diarrhoea or colitis has been observed with nivolumab treatment (see section 4.8). Patients should be monitored for diarrhoea and additional symptoms of colitis, such as abdominal pain and mucus or blood in stool. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-related colitis. Infectious and other aetiologies of diarrhoea should be ruled out, therefore appropriate laboratory tests and additional examinations must be performed. If diagnosis of corticosteroid-refractory immune-related colitis is confirmed addition of an alternative immunosuppressive agent to the corticosteroid therapy, or replacement of the corticosteroid therapy, should be considered.

For Grade 4 diarrhoea or colitis, nivolumab must be permanently discontinued, and corticosteroids should be initiated at a dose of 1 to 2 mg/kg/day methylprednisolone equivalents.

For Grade 3 diarrhoea or colitis, nivolumab should be withheld and corticosteroids initiated at a dose of 1 to 2 mg/kg/day methylprednisolone equivalents. Upon improvement, nivolumab may be resumed after corticosteroid taper. If worsening or no improvement occurs despite initiation of corticosteroids, nivolumab must be permanently discontinued.

For Grade 2 diarrhoea or colitis, nivolumab should be withheld. Persistent diarrhoea or colitis should be managed with corticosteroids at a dose of 0.5 to 1 mg/kg/day methylprednisolone equivalents. Upon improvement, nivolumab may be resumed after corticosteroid taper, if needed. If worsening or no improvement occurs despite initiation of corticosteroids, corticosteroid dose should be increased

to 1 to 2 mg/kg/day methylprednisolone equivalents and nivolumab must be permanently discontinued.

#### Immune-related hepatitis

Severe hepatitis has been observed with nivolumab treatment (see section 4.8). Patients should be monitored for signs and symptoms of hepatitis such as transaminase and total bilirubin elevations. Infectious and disease-related aetiologies should be ruled out.

For Grade 3 or 4 transaminase or total bilirubin elevation, nivolumab must be permanently discontinued, and corticosteroids should be initiated at a dose of 1 to 2 mg/kg/day methylprednisolone equivalents.

For Grade 2 transaminase or total bilirubin elevation, nivolumab should be withheld. Persistent elevations in these laboratory values should be managed with corticosteroids at a dose of 0.5 to 1 mg/kg/day methylprednisolone equivalents. Upon improvement, nivolumab may be resumed after corticosteroid taper, if needed. If worsening or no improvement occurs despite initiation of corticosteroids, corticosteroid dose should be increased to 1 to 2 mg/kg/day methylprednisolone equivalents and nivolumab must be permanently discontinued.

#### Immune-related nephritis or renal dysfunction

Severe nephritis and renal dysfunction has been observed with nivolumab treatment (see section 4.8). Patients should be monitored for signs and symptoms of nephritis and renal dysfunction. Most patients present with asymptomatic increases in serum creatinine. Disease-related aetiologies should be ruled out.

For Grade 4 serum creatinine elevation, nivolumab must be permanently discontinued, and corticosteroids should be initiated at a dose of 1 to 2 mg/kg/day methylprednisolone equivalents.

For Grade 2 or 3 serum creatinine elevation, nivolumab should be withheld, and corticosteroids should be initiated at a dose of 0.5 to 1 mg/kg/day methylprednisolone equivalents. Upon improvement, nivolumab may be resumed after corticosteroid taper. If worsening or no improvement occurs despite initiation of corticosteroids, corticosteroid dose should be increased to 1 to 2 mg/kg/day methylprednisolone equivalents, and nivolumab must be permanently discontinued.

#### Immune-related endocrinopathies

Severe endocrinopathies, including hypothyroidism, hyperthyroidism, adrenal insufficiency (including secondary adrenocortical insufficiency), hypophysitis (including hypopituitarism), diabetes mellitus, and diabetic ketoacidosis have been observed with nivolumab treatment (see section 4.8).

Patients should be monitored for clinical signs and symptoms of endocrinopathies and for changes in thyroid function (at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation). Patients may present with fatigue, headache, mental status changes, abdominal pain, unusual bowel habits, and hypotension, or nonspecific symptoms which may resemble other causes such as brain metastasis or underlying disease. Unless an alternate aetiology has been identified, signs or symptoms of endocrinopathies should be considered immune-related.

For symptomatic hypothyroidism, nivolumab should be withheld, and thyroid hormone replacement should be initiated as needed. For symptomatic hyperthyroidism, nivolumab should be withheld and antithyroid medication should be initiated as needed. Corticosteroids at a dose of 1 to 2 mg/kg/day methylprednisolone equivalents should also be considered if acute inflammation of the thyroid is suspected. Upon improvement, nivolumab may be resumed after corticosteroid taper, if needed. Monitoring of thyroid function should continue to ensure appropriate hormone replacement is utilised. Nivolumab must be permanently discontinued for life-threatening hyperthyroidism or hypothyroidism.

For symptomatic Grade 2 adrenal insufficiency, nivolumab should be withheld, and physiologic corticosteroid replacement should be initiated as needed. Nivolumab must be permanently discontinued for severe (Grade 3) or life-threatening (Grade 4) adrenal insufficiency. Monitoring of

adrenal function and hormone levels should continue to ensure appropriate corticosteroid replacement is utilised.

For symptomatic Grade 2 or 3 hypophysitis, nivolumab should be withheld, and hormone replacement should be initiated as needed. Corticosteroids at a dose of 1 to 2 mg/kg/day methylprednisolone equivalents should also be considered if acute inflammation of the pituitary gland is suspected. Upon improvement, nivolumab may be resumed after corticosteroid taper, if needed. Nivolumab must be permanently discontinued for life-threatening (Grade 4) hypophysitis. Monitoring of pituitary function and hormone levels should continue to ensure appropriate hormone replacement is utilised.

For symptomatic diabetes, nivolumab should be withheld, and insulin replacement should be initiated as needed. Monitoring of blood sugar should continue to ensure appropriate insulin replacement is utilised. . Nivolumab must be permanently discontinued for life-threatening diabetes.

#### Immune-related skin adverse reactions

Severe rash has been observed less commonly, with nivolumab as monotherapy (see section 4.8). Nivolumab should be withheld for Grade 3 rash and discontinued for Grade 4 rash. Severe rash should be managed with high-dose corticosteroid at a dose of 1 to 2 mg/kg/day methylprednisolone equivalents.

Rare cases of SJS and TEN some of them with fatal outcome have been observed. If symptoms or signs of SJS or TEN appear, treatment with nivolumab should be discontinued and the patient referred to a specialised unit for assessment and treatment. If the patient has developed SJS or TEN with the use of nivolumab permanent discontinuation of treatment is recommended (see section 4.2).

Caution should be used when considering the use of nivolumab in a patient who has previously experienced a severe or life-threatening skin adverse reaction on prior treatment with other immune-stimulatory anticancer agents.

#### Other immune-related adverse reactions

The following immune-related adverse reactions were reported in less than 1% of patients treated with nivolumab in clinical trials across doses and tumour types: pancreatitis, uveitis, demyelination, autoimmune neuropathy (including facial and abducens nerve paresis), Guillain-Barré syndrome, myasthenia gravis, myasthenic syndrome, aseptic meningitis, gastritis, sarcoidosis, duodenitis, encephalitis, myositis, myocarditis, rhabdomyolysis and myelitis. Cases of Vogt-Koyanagi-Harada syndrome have been reported post-marketing (see section 4.8).

For suspected immune-related adverse reactions, adequate evaluation should be performed to confirm etiology or exclude other causes. Based on the severity of the adverse reaction, nivolumab should be withheld and corticosteroids administered. Upon improvement, nivolumab may be resumed after corticosteroid taper. Nivolumab must be permanently discontinued for any severe immune-related adverse reaction that recurs and for any life-threatening immune-related adverse reaction.

Cases of myotoxicity (myositis, myocarditis, and rhabdomyolysis), some with fatal outcome, have been reported with nivolumab. If a patient develops signs and symptoms of myotoxicity, close monitoring should be implemented, and the patient referred to a specialist for assessment and treatment without delay. Based on the severity of myotoxicity, nivolumab should be withheld or discontinued (see section 4.2), and appropriate treatment instituted.

The diagnosis of myocarditis requires a high index of suspicion. Patients with cardiac or cardio-pulmonary symptoms should be assessed for potential myocarditis. If myocarditis is suspected, prompt initiation of a high dose of steroids (prednisone 1 to 2 mg/kg/day or methylprednisolone 1 to 2 mg/kg/day) and prompt cardiology consultation with diagnostic workup according to current clinical guidelines should be initiated. Once a diagnosis of myocarditis is established, nivolumab treatment should be withheld or permanently discontinued (see section 4.2).

Solid organ transplant rejection has been reported in the post-marketing setting in patients treated with PD-1 inhibitors. Treatment with nivolumab may increase the risk of rejection in solid organ transplant recipients. The benefit of treatment with nivolumab versus the risk of possible organ rejection should be considered in these patients.

Rapid-onset and severe graft-versus-host disease (GVHD), some with fatal outcome, has been reported in the postmarketing setting in patients who had undergone prior allogeneic stem cell transplant and subsequently received PD-1/PD-L1 inhibitors.

Haemophagocytic lymphohistiocytosis (HLH) has been observed with nivolumab as monotherapy. Caution should be taken when nivolumab is administered as monotherapy. If HLH is confirmed, administration of nivolumab should be discontinued and treatment for HLH initiated.

#### Infusion reactions

Severe infusion reactions have been reported in clinical trials (see section 4.8). In case of a severe or life-threatening infusion reaction, the nivolumab infusion must be discontinued and appropriate medical therapy administered. Patients with mild or moderate infusion reaction may receive nivolumab with close monitoring and use of premedication according to local treatment guidelines for prophylaxis of infusion reactions.

#### Disease-specific precautions

##### *Melanoma*

Patients with a baseline performance score  $\geq 2$ , active brain metastases or autoimmune disease, and patients who had been receiving systemic immunosuppressants prior to study entry were excluded from the clinical trials of nivolumab. Patients with ocular/uveal melanoma were excluded from pivotal clinical trials of melanoma. In addition, CA209037 excluded patients who have had a Grade 4 adverse reaction that was related to anti-CTLA-4 therapy (see section 5.1). In the absence of data, nivolumab should be used with caution in these populations after careful consideration of the potential benefit/risk on an individual basis.

##### *Adjuvant treatment of melanoma*

There are no data on adjuvant treatment in patients with melanoma with the following risk factors (see sections 4.5 and 5.1):

- patients with prior autoimmune disease, and any condition requiring systemic treatment with either corticosteroids ( $\geq 10$  mg daily prednisone or equivalent) or other immunosuppressive medications,
- patients with prior therapy for melanoma (except patients with surgery, adjuvant radiotherapy after neurosurgical resection for lesions of the central nervous system, and prior adjuvant interferon completed  $\geq 6$  months prior to randomisation),
- patients treated with prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways),
- subjects under the age of 18 years.

In the absence of data, nivolumab should be used with caution in these populations after careful consideration of the potential benefit/risk on an individual basis.

##### *Non-Small Cell Lung Cancer*

Patients with a baseline performance score  $\geq 2$ , active brain metastases or autoimmune disease, symptomatic interstitial lung disease, and patients who had been receiving systemic immunosuppressants prior to study entry were excluded from the clinical trials of NSCLC (see sections 4.5 and 5.1). In the absence of data, nivolumab should be used with caution in these populations after careful consideration of the potential benefit/risk on an individual basis.

Physicians should consider the delayed onset of nivolumab effect before initiating treatment in patients with poorer prognostic features and/or aggressive disease. In non-squamous NSCLC, a higher number of deaths within 3 months was observed in nivolumab compared to docetaxel. Factors

associated with early deaths were poorer prognostic factors and/or more aggressive disease combined with low or no tumour PD-L1 expression (see section 5.1).

#### Neoadjuvant treatment of NSCLC

Patients with a baseline performance score  $\geq 2$ , active autoimmune disease, symptomatic interstitial lung disease, medical conditions requiring systemic immunosuppression, unresectable or metastatic disease, who received prior anti-cancer treatment for resectable disease, or who had known EGFR mutations or ALK translocations were excluded from the pivotal trial in neoadjuvant treatment of resectable NSCLC (see sections 5.1). In the absence of data, nivolumab in combination with chemotherapy should be used with caution in these populations after careful consideration of the potential benefit/risk on an individual basis.

#### Neoadjuvant and adjuvant treatment of non-small cell lung cancer

Patients with a baseline performance score  $\geq 2$ , Grade 2 or greater peripheral neuropathy, active autoimmune disease, symptomatic interstitial lung disease, medical conditions requiring systemic immunosuppression, unresectable or metastatic disease, who received prior anti-cancer treatment for resectable disease, who had EGFR mutations or known ALK translocations, or who had brain metastasis, were excluded from the pivotal trial in neoadjuvant and adjuvant treatment of NSCLC (see sections 4.5 and 5.1). In the absence of data, nivolumab in combination with chemotherapy should be used with caution in these populations after careful consideration of the potential benefit/risk on an individual basis.

#### Renal Cell Carcinoma

##### Nivolumab monotherapy

Patients with any history of or concurrent brain metastases, active autoimmune disease, or medical conditions requiring systemic immunosuppression were excluded from the clinical trials of nivolumab (see sections 4.5 and 5.1). In the absence of data, nivolumab should be used with caution in these populations after careful consideration of the potential benefit/risk on an individual basis.

Increased mortality in patients with multiple myeloma when a PD-1 blocking antibody is added to a thalidomide analogue and dexamethasone.

In randomized clinical trials in patients with multiple myeloma, the addition of a PD-1 blocking antibody, including nivolumab, to a thalidomide analogue plus dexamethasone, a use for which no PD-1 blocking antibody is indicated, resulted in increased mortality. Treatment of patients with multiple myeloma with a PD-1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials.

##### Nivolumab in combination with cabozantinib

Patients with any active brain metastases, autoimmune disease, or medical conditions requiring systemic immunosuppression were excluded from the clinical trials of nivolumab in combination with cabozantinib (see sections 4.5 and 5.1). In the absence of data, nivolumab in combination with cabozantinib should be used with caution in these populations after careful consideration of the potential benefit/risk on an individual basis.

When nivolumab is given with cabozantinib, higher frequencies of Grades 3 and 4 ALT and AST elevations have been reported relative to nivolumab monotherapy in patients with advanced RCC (see section 4.8). Liver enzymes should be monitored before initiation of and periodically throughout treatment. Medical management guidelines for both medicines should be followed (see section 4.2 and refer to the package insert for cabozantinib).

#### Gastric, gastro-oesophageal junction or oesophageal adenocarcinoma

Patients who had baseline ECOG performance score  $\geq 2$ , untreated central nervous system metastases, active, known, or suspected autoimmune disease, or medical conditions requiring systemic immunosuppression were excluded from the clinical study in gastric, GEJ or oesophageal adenocarcinoma (see sections 4.5 and 5.1). In the absence of data, nivolumab in combination with chemotherapy should be used with caution in these populations after careful consideration of the potential benefit/risk on an individual basis.

Study CA209649 excluded patients with known HER2-positive status. Patients with undetermined status were allowed in the study and represented 40.3% of patients (see section 5.1).

#### Patients on controlled sodium diet

Each mL of this medicinal product contains 0.1 mmol (or 2.5 mg) sodium. To be taken into consideration when treating patients on a controlled sodium diet.

### **4.5 Interaction with other medicinal products and other forms of interaction**

Nivolumab is a human monoclonal antibody, as such pharmacokinetic interaction studies have not been conducted. As monoclonal antibodies are not metabolised by cytochrome P450 (CYP) enzymes or other drug metabolising enzymes, inhibition or induction of these enzymes by co-administered medicinal products is not anticipated to affect the pharmacokinetics of nivolumab.

#### Other forms of interaction

##### Systemic immunosuppression

The use of systemic corticosteroids and other immunosuppressants at baseline, before starting nivolumab, should be avoided because of their potential interference with the pharmacodynamic activity. However, systemic corticosteroids and other immunosuppressants can be used after starting nivolumab to treat immune-related adverse reactions. The preliminary results show that systemic immunosuppression after starting nivolumab treatment does not appear to preclude the response on nivolumab.

### **4.6 Fertility, pregnancy and lactation**

#### Pregnancy

There are no data on the use of nivolumab in pregnant women. Studies in animals have shown embryofoetal toxicity (see section 5.3). Human IgG4 is known to cross the placental barrier and nivolumab is an IgG4; therefore nivolumab has the potential to be transmitted from the mother to the developing foetus. Nivolumab is not recommended during pregnancy and in women of childbearing potential not using effective contraception unless the clinical benefit outweighs the potential risk. Effective contraception should be used for at least 5 months following the last dose of nivolumab.

#### Breast-feeding

It is unknown whether nivolumab is secreted in human milk. Because many medicinal products, including antibodies, can be secreted in human milk, a risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue from nivolumab therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

#### Fertility

Studies to evaluate the effect of nivolumab on fertility have not been performed. Thus, the effect of nivolumab on male and female fertility is unknown.

### **4.7 Effects on ability to drive and use machines**

Based on its pharmacodynamic properties, nivolumab is unlikely to affect the ability to drive and use machines. Because of potential adverse reactions such as fatigue (see section 4.8), patients should be advised to use caution when driving or operating machinery until they are certain that nivolumab does not adversely affect them.

## 4.8 Undesirable effects

The safety data in this section are derived from pooled clinical trials across multiple tumour types and may include indications not currently approved in Malaysia.

### Nivolumab as monotherapy (see section 4.2)

#### *Summary of the safety profile*

In the pooled dataset of nivolumab as monotherapy across tumour types (n = 4646) with minimum follow-up ranging from 2.3 to 28 months, the most frequent adverse reactions ( $\geq 10\%$ ) were fatigue (44%), musculoskeletal pain (28%), diarrhoea (26%), rash (24%), cough (22%), nausea (22%), pruritus (19%), decreased appetite (17%), arthralgia (17%), constipation (16%), dyspnoea (16%), abdominal pain (15%), upper respiratory tract infection (15%), pyrexia (13%), headache (13%), anaemia (13%) and vomiting (12%). The majority of adverse reactions were mild to moderate (Grade 1 or 2). The incidence of Grade 3-5 adverse reactions was 44%, with 0.3% fatal adverse reactions attributed to study drug. With a minimum of 63 months follow-up in NSCLC, no new safety signals were identified.

#### *Tabulated summary of adverse reactions*

Adverse reactions reported in the pooled dataset for patients treated with nivolumab monotherapy (n = 4646) are presented in Table 3. These reactions are presented by system organ class and by frequency. Frequencies are defined as: very common ( $\geq 1/10$ ); common ( $\geq 1/100$  to  $< 1/10$ ); uncommon ( $\geq 1/1,000$  to  $< 1/100$ ); rare ( $\geq 1/10,000$  to  $< 1/1,000$ ); very rare ( $< 1/10,000$ ); not known (cannot be estimated from available post-marketing data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.

**Table 3: Adverse reactions with nivolumab monotherapy**

	<b>nivolumab monotherapy</b>
<b>Infections and infestations</b>	
Very common	upper respiratory tract infection
Common	pneumonia <sup>a</sup> , bronchitis
Rare	aseptic meningitis
<b>Neoplasms benign, malignant and unspecified (including cysts and polyps)</b>	
Rare	histiocytic necrotising lymphadenitis (Kikuchi lymphadenitis)
<b>Blood and lymphatic system disorders</b>	
Very common	lymphopaenia <sup>b</sup> , anaemia <sup>b,i</sup> , leucopenia <sup>b</sup> , neutropaenia <sup>a,b</sup> , thrombocytopaenia <sup>b</sup>
Uncommon	eosinophilia
Not known	haemophagocytic lymphohistiocytosis
<b>Immune system disorders</b>	
Common	infusion related reaction (including cytokine release syndrome), hypersensitivity (including anaphylactic reaction)
Uncommon	sarcoidosis
Not known	solid organ transplant rejection <sup>f</sup>
<b>Endocrine disorders</b>	
Common	hypothyroidism, hyperthyroidism, thyroiditis
Uncommon	adrenal insufficiency <sup>j</sup> , hypopituitarism, hypophysitis, diabetes mellitus
Rare	diabetic ketoacidosis, hypoparathyroidism
<b>Metabolism and nutrition disorders</b>	
Very common	decreased appetite, hyperglycaemia <sup>b</sup>
Common	dehydration, weight decreased, hypoglycaemia <sup>b</sup>
Uncommon	metabolic acidosis
Not known	tumour lysis syndrome <sup>g</sup>

<b>Nervous system disorders</b>	
Very common	headache
Common	peripheral neuropathy, dizziness
Uncommon	polyneuropathy, autoimmune neuropathy (including facial and abducens nerve paresis)
Rare	Guillain-Barré syndrome, demyelination, myasthenic syndrome, encephalitis <sup>a,k</sup>
Not known	myelitis (including transverse myelitis)
<b>Eye disorders</b>	
Common	blurred vision, dry eye
Uncommon	uveitis
Not known	Vogt-Koyanagi-Harada syndrome <sup>f</sup>
<b>Cardiac disorders</b>	
Common	tachycardia, atrial fibrillation
Uncommon	myocarditis <sup>a</sup> , pericardial disorders <sup>h</sup> , arrhythmia (including ventricular arrhythmia)
<b>Vascular disorders</b>	
Common	hypertension
Rare	vasculitis
<b>Respiratory, thoracic and mediastinal disorders</b>	
Very common	dyspnoea <sup>a</sup> , cough
Common	pneumonitis <sup>a</sup> , pleural effusion
Uncommon	lung infiltration
<b>Gastrointestinal disorders</b>	
Very common	diarrhoea, vomiting, nausea, abdominal pain, constipation
Common	colitis <sup>a</sup> , stomatitis, dry mouth
Uncommon	pancreatitis, gastritis
Rare	duodenal ulcer
<b>Hepatobiliary disorders</b>	
Uncommon	hepatitis, cholestasis
<b>Skin and subcutaneous tissue disorders</b>	
Very common	rash <sup>c</sup> , pruritus
Common	vitiligo, dry skin, erythema, alopecia
Uncommon	psoriasis, rosacea, erythema multiforme, urticaria
Rare	toxic epidermal necrolysis <sup>a,d</sup> , Stevens-Johnson syndrome <sup>a</sup>
Not known	lichen sclerosus <sup>g</sup> , other lichen disorders
<b>Musculoskeletal and connective tissue disorders</b>	
Very common	musculoskeletal pain <sup>c</sup> , arthralgia
Common	arthritis
Uncommon	polymyalgia rheumatica
Rare	Sjogren's syndrome, myopathy, myositis (including polymyositis) <sup>a</sup> , rhabdomyolysis <sup>a,d</sup>
<b>Renal and urinary disorders</b>	
Common	renal failure (including acute kidney injury) <sup>a</sup>
Rare	tubulointerstitial nephritis, cystitis noninfective

<b>General disorders and administration site conditions</b>	
Very common	fatigue, pyrexia
Common	pain, chest pain, oedema <sup>l</sup>
<b>Investigations<sup>b</sup></b>	
Very common	increased AST, hyponatraemia, hypoalbuminaemia, increased alkaline phosphatase, increased creatinine, increased ALT, increased lipase, hyperkalaemia, increased amylase, hypocalcaemia, hypomagnesaemia, hypokalaemia, hypercalcaemia
Common	increased total bilirubin, hypernatraemia, hypermagnesaemia,

Adverse reaction frequencies presented in Table 3 may not be fully attributable to nivolumab alone but may contain contributions from the underlying disease.

- <sup>a</sup> Fatal cases have been reported in completed or ongoing clinical studies
- <sup>b</sup> Frequencies of laboratory terms reflect the proportion of patients who experienced a worsening from baseline in laboratory measurements. See “Description of selected adverse reactions; laboratory abnormalities” below.
- <sup>c</sup> Rash is a composite term which includes rash maculopapular, rash erythematous, rash pruritic, rash follicular, rash macular, rash morbilliform, rash papular, rash pustular, rash vesicular, exfoliative rash, dermatitis, dermatitis acneiform, dermatitis allergic, dermatitis atopic, dermatitis bullous, dermatitis exfoliative, dermatitis psoriasiform, drug eruption and pemphigoid.
- <sup>d</sup> Reported also in studies outside the pooled dataset. The frequency is based on the program-wide exposure.
- <sup>e</sup> Musculoskeletal pain is a composite term which includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, myalgia, myalgia intercostal, neck pain, pain in extremity, and spinal pain.
- <sup>f</sup> Post-marketing event (also see section 4.4)
- <sup>g</sup> Reported in clinical studies and in the post-marketing setting.
- <sup>h</sup> Pericardial disorders is a composite term which includes pericarditis, pericardial effusion, cardiac tamponade, and Dressler’s syndrome.
- <sup>i</sup> Anaemia is a composite term which includes, among other causes, haemolytic anaemia and autoimmune anaemia, haemoglobin decreased, iron deficiency anaemia and red blood cell count decreased.
- <sup>j</sup> Includes adrenal insufficiency, adrenocortical insufficiency acute, and secondary adrenocortical insufficiency.
- <sup>k</sup> Includes encephalitis and limbic encephalitis.
- <sup>l</sup> Oedema is a composite term which includes generalised oedema, oedema peripheral, peripheral swelling and swelling.

The overall safety profile of nivolumab 3 mg/kg for the adjuvant treatment of melanoma (n = 452) was consistent with that established across tumour types for nivolumab monotherapy.

#### Nivolumab in combination with other therapeutic agents (see section 4.2)

##### *Summary of the safety profile*

When nivolumab is administered in combination, refer to the package insert for the respective combination therapy components prior to initiation of treatment.

##### *Nivolumab in combination with chemotherapy*

In the pooled dataset of nivolumab 240 mg every 2 weeks or 360 mg every 3 weeks in combination with chemotherapy across tumour types (n = 1800), with a minimum follow-up ranging from 7.4 to 23.6 months, or following 3 cycles of treatment for resectable NSCLC, the most frequent adverse reactions ( $\geq 10\%$ ) were nausea (48%), fatigue (40%), peripheral neuropathy (33%), decreased appetite (31%), constipation (31%), diarrhoea (28%), vomiting (24%), rash (19%), abdominal pain (18%), stomatitis (18%), musculoskeletal pain (18%), pyrexia (16%), cough (13%), oedema (including peripheral oedema) (12%) and pruritus (11%). Incidences of Grade 3-5 adverse reactions were 69% for nivolumab in combination with chemotherapy, with 1.2% fatal adverse reactions attributed to nivolumab in combination with chemotherapy. Median duration of therapy was 6.14 months (95% CI: 5.78, 6.60) for nivolumab in combination with chemotherapy. For resectable NSCLC,

ninety-three percent (93%) of patients received 3 cycles of nivolumab in combination with chemotherapy.

*Tabulated summary of adverse reactions*

Adverse reactions reported in the pooled dataset for patients treated with nivolumab in combination with chemotherapy (n = 1800) are presented in Table 4. These reactions are presented by system organ class and by frequency. Frequencies are defined as: very common ( $\geq 1/10$ ); common ( $\geq 1/100$  to  $< 1/10$ ); uncommon ( $\geq 1/1,000$  to  $< 1/100$ ); rare ( $\geq 1/10,000$  to  $< 1/1,000$ ); very rare ( $< 1/10,000$ ), not known (cannot be estimated from available post-marketing data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.

**Table 4: Adverse reactions with nivolumab in combination with other therapeutic agents**

<b>Nivolumab in combination with chemotherapy</b>	
<b>Infections and infestations</b>	
Common	upper respiratory tract infection, pneumonia <sup>a</sup>
<b>Blood and lymphatic system disorders</b>	
Very common	neutropaenia <sup>b</sup> , anaemia <sup>b,c</sup> , leucopenia <sup>b</sup> , lymphopaenia <sup>b</sup> , thrombocytopenia <sup>b</sup>
Common	febrile neutropaenia <sup>a</sup>
Uncommon	eosinophilia
<b>Immune system disorders</b>	
Common	hypersensitivity, infusion related reaction (including cytokine release syndrome)
<b>Endocrine disorders</b>	
Common	hypothyroidism, hyperthyroidism, diabetes mellitus
Uncommon	adrenal insufficiency, thyroiditis, hypopituitarism, hypophysitis
<b>Metabolism and nutrition disorders</b>	
Very common	decreased appetite, hyperglycaemia <sup>b</sup> , hypoglycaemia <sup>b</sup>
Common	hypoalbuminaemia, hypophosphataemia
Rare	tumour lysis syndrome
<b>Nervous system disorders</b>	
Very common	peripheral neuropathy
Common	paraesthesia, dizziness, headache
Uncommon	Guillain-Barré syndrome
Rare	encephalitis
Not known	myelitis (including transverse myelitis)
<b>Eye disorders</b>	
Common	dry eye, blurred vision
Uncommon	uveitis
<b>Cardiac disorders</b>	

Common	tachycardia, atrial fibrillation
Uncommon	myocarditis
<b>Vascular disorders</b>	
Common	thrombosis <sup>a,f</sup> , hypertension, vasculitis
<b>Respiratory, thoracic and mediastinal disorders</b>	
Very common	cough
Common	pneumonitis <sup>a</sup> , dyspnoea
<b>Gastrointestinal disorders</b>	
Very common	diarrhoea <sup>a</sup> , stomatitis, vomiting, nausea, abdominal pain, constipation
Common	colitis, dry mouth
Uncommon	pancreatitis
<b>Hepatobiliary disorders</b>	
Uncommon	hepatitis
<b>Skin and subcutaneous tissue disorders</b>	
Very common	rash <sup>c</sup> , pruritus
Common	palmar-plantar erythrodysesthesia syndrome, skin hyperpigmentation, alopecia, dry skin, erythema
<b>Musculoskeletal and connective tissue disorders</b>	
Very common	musculoskeletal pain <sup>d</sup>
Common	arthralgia, muscular weakness
<b>Renal and urinary disorders</b>	
Common	renal failure <sup>a</sup>
Uncommon	cystitis noninfective, nephritis
<b>General disorders and administration site conditions</b>	
Very common	fatigue, pyrexia, oedema (including peripheral oedema)
Common	malaise
<b>Investigations</b>	
Very common	hypocalcaemia <sup>b</sup> , increased AST <sup>b</sup> , increased ALT <sup>b</sup> , hyponatraemia <sup>b</sup> , increased amylase <sup>b</sup> , hypomagnesaemia <sup>b</sup> , increased alkaline phosphatase <sup>b</sup> , hypokalaemia <sup>b</sup> , increased creatinine <sup>b</sup> , increased lipase <sup>b</sup> , hyperkalaemia <sup>b</sup> , increased total bilirubin <sup>b</sup>
Common	hypernatraemia <sup>b</sup> , hypercalcaemia <sup>b</sup> , hypermagnesaemia <sup>b</sup>

Adverse reaction frequencies presented in Table 4 may not be fully attributable to nivolumab alone or in combination with other therapeutic agents, but may contain contributions from the underlying disease or from medicinal product used in combination.

<sup>a</sup> Fatal cases have been reported in completed or ongoing clinical studies.

<sup>b</sup> Frequencies of laboratory terms reflect the proportion of patients who experienced a worsening from baseline in laboratory measurements. See “Description of selected adverse reactions; laboratory abnormalities” below.

<sup>c</sup> Rash is a composite term which includes maculopapular rash, rash erythematous, rash pruritic, rash follicular, rash macular, rash morbilliform, rash papular, rash pustular, rash papulosquamous, rash vesicular, rash generalised, exfoliative rash, dermatitis, dermatitis acneiform, dermatitis allergic, dermatitis atopic, dermatitis bullous, dermatitis exfoliative, dermatitis psoriasiform, drug eruption, nodular rash, and pemphigoid.

<sup>d</sup> Musculoskeletal pain is a composite term which includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, myalgia, myalgia intercostal, neck pain, pain in extremity, and spinal pain.

<sup>e</sup> Anaemia is a composite term which includes, among other causes, haemolytic anaemia and autoimmune anaemia, haemoglobin decreased, iron deficiency anaemia and red blood cell count decreased.

<sup>f</sup> Thrombosis is a composite term which includes portal vein thrombosis, pulmonary vein thrombosis, pulmonary thrombosis, aortic thrombosis, arterial thrombosis, deep vein thrombosis, pelvic vein thrombosis, vena cava thrombosis, venous thrombosis, limb venous thrombosis.

## Nivolumab in combination with cabozantinib (see section 4.2)

### *Summary of the safety profile*

When nivolumab is administered in combination with cabozantinib, refer to the package insert for cabozantinib prior to initiation of treatment. For additional information on the safety profile of cabozantinib monotherapy, please refer to the cabozantinib package insert.

### RCC

In the dataset of nivolumab 240 mg every 2 weeks in combination with cabozantinib 40 mg once daily in RCC (n = 320), with a minimum follow-up of 16.0 months, the most frequent adverse reactions ( $\geq 10\%$ ) were diarrhoea (64.7%), fatigue (51.3%), palmar plantar erythrodysesthesia syndrome (40.0%), stomatitis (38.8%), musculoskeletal pain (37.5%), hypertension (37.2%), rash (36.3%), hypothyroidism (35.6%), decreased appetite (30.3%), nausea (28.8%), abdominal pain (25.0%), dysgeusia (23.8%), upper respiratory tract infection (20.6%), cough (20.6%), pruritus (20.6%), arthralgia (19.4%), vomiting (18.4%), dysphonia (17.8%), headache (16.3%), dyspepsia (15.9%), dizziness (14.1%), constipation (14.1%), pyrexia (14.1%), oedema (13.4%), muscle spasm (12.2%), dyspnoea (11.6%), proteinuria (10.9%) and hyperthyroidism (10.0%). The majority of adverse reactions were mild to moderate (Grade 1 or 2).

### *Tabulated summary of adverse reactions*

Adverse reactions reported in the dataset for patients treated with nivolumab 240 mg in combination with cabozantinib 40 mg (n = 320) are presented in Table 5. These reactions are presented by system organ class and by frequency. Frequencies are defined as: very common ( $\geq 1/10$ ); common ( $\geq 1/100$  to  $< 1/10$ ); uncommon ( $\geq 1/1,000$  to  $< 1/100$ ). Not known (cannot be estimated from available post-marketing data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.

**Table 5: Adverse reactions with nivolumab in combination with cabozantinib**

<b>Infections and infestations</b>	
Very Common	upper respiratory tract infection
Common	pneumonia
<b>Blood and lymphatic system disorders</b>	
Very common	anaemia <sup>e</sup> , thrombocytopaenia <sup>e</sup> , leucopenia <sup>e</sup> , lymphopaenia <sup>e</sup> , neutropaenia <sup>e</sup> ,
Common	eosinophilia
<b>Immune system disorders</b>	
Common	hypersensitivity (including anaphylactic reaction)
Uncommon	infusion related hypersensitivity reaction
<b>Endocrine disorders</b>	
Very common	hypothyroidism, hyperthyroidism
Common	adrenal insufficiency
Uncommon	hypophysitis, thyroiditis
<b>Metabolism and nutrition disorders</b>	
Very common	decreased appetite, hypoglycaemia <sup>e</sup> , hyperglycaemia <sup>e</sup> , weight decreased
Common	dehydration
<b>Nervous system disorders</b>	
Very common	dysgeusia, dizziness, headache
Common	peripheral neuropathy
Uncommon	encephalitis autoimmune, Guillain-Barré syndrome, myasthenic syndrome
<b>Ear and labyrinth disorders</b>	
Common	tinnitus
<b>Eye disorders</b>	
Common	dry eye, blurred vision
Uncommon	uveitis
<b>Cardiac disorders</b>	
Common	atrial fibrillation, tachycardia
Uncommon	myocarditis
<b>Vascular disorders</b>	
Very common	hypertension
Common	thrombosis <sup>a</sup>
<b>Respiratory, thoracic and mediastinal disorders</b>	
Very common	dysphonia, dyspnoea, cough
Common	pneumonitis, pulmonary embolism, pleural effusion, epistaxis
<b>Gastrointestinal disorders</b>	
Very common	diarrhoea, vomiting, nausea, constipation, stomatitis, abdominal pain, dyspepsia
Common	colitis, gastritis, oral pain, dry mouth, haemorrhoids
Uncommon	pancreatitis, small intestine perforation <sup>b</sup> , glossodynia
<b>Hepatobiliary disorders</b>	
Common	hepatitis
<b>Skin and subcutaneous tissue disorders</b>	
Very common	palmar-plantar erythrodysesthesia syndrome, rash <sup>c</sup> , pruritus
Common	alopecia, dry skin, erythema, hair colour change
Uncommon	psoriasis, urticaria
<b>Musculoskeletal and connective tissue disorders</b>	
Very common	musculoskeletal pain <sup>d</sup> , arthralgia, muscle spasm
Common	arthritis
Uncommon	myopathy, osteonecrosis of the jaw, fistula
<b>Renal and urinary disorders</b>	
Very common	proteinuria

Common	renal failure, acute kidney injury
Uncommon	nephritis
Rare	cystitis noninfective <sup>f</sup>
<b>General disorders and administration site conditions</b>	
Very common	fatigue, pyrexia, oedema
Common	pain, chest pain
<b>Investigations<sup>e</sup></b>	
Very common	increased alkaline phosphatase, increased ALT, increased AST, increased total bilirubin, increased creatinine, increased amylase, increased lipase, hypokalaemia, hypomagnesaemia, hyponatraemia, hypocalcaemia, hypercalcaemia, hypophosphataemia, hyperkalaemia, hypermagnesaemia, hypernatraemia,
Common	blood cholesterol increased, hypertriglyceridaemia

Adverse reaction frequencies presented in Table 5 may not be fully attributable to nivolumab alone but may contain contributions from the underlying disease or from medicinal product used in combination.

<sup>a</sup> Thrombosis is a composite term which includes portal vein thrombosis, pulmonary vein thrombosis, pulmonary thrombosis, aortic thrombosis, arterial thrombosis, deep vein thrombosis, pelvic vein thrombosis, vena cava thrombosis, venous thrombosis, limb venous thrombosis.

<sup>b</sup> Fatal cases have been reported.

<sup>c</sup> Rash is a composite term which includes dermatitis, dermatitis anaceiform, dermatitis allergic, dermatitis atopic, dermatitis bullous, exfoliative rash, rash erythematous, rash follicular, rash macular, rash maculo-papular, rash papular, rash morbilliform, rash pruritic, and drug eruption.

<sup>d</sup> Musculoskeletal pain is a composite term which includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, myalgia, neck pain, pain in extremity, spinal pain.

<sup>e</sup> Frequencies of laboratory terms reflect the proportion of patients who experienced a worsening from baseline in laboratory measurements (with the exception of, blood cholesterol increased, and hypertriglyceridaemia). See “Description of selected adverse reactions; laboratory abnormalities” below.

<sup>f</sup> Reported in clinical studies and in the post-marketing setting.

### Description of selected adverse reactions

Data for the following immune-related adverse reactions are based on patients who received nivolumab 3 mg/kg as monotherapy and combination with cabozantinib. The management guidelines for these adverse reactions are described in section 4.4.

#### Immune-related pneumonitis

In patients treated with nivolumab monotherapy, the incidence of pneumonitis, including interstitial lung disease and lung infiltration, was 3.3% (155/4646). The majority of cases were Grade 1 or 2 in severity reported in 0.9% (42/4646) and 1.7% (77/4646) of patients respectively. Grade 3 and 4 cases were reported in 0.7% (33/4646) and <0.1% (1/4646) of patients respectively. Six patients (0.1%) had a fatal outcome. Median time to onset was 15.1 weeks (range: 0.7-85.1). Resolution occurred in 107 patients (69.0%) with a median time to resolution of 6.7 weeks (range: 0.1<sup>+</sup>-109.1<sup>+</sup>); <sup>+</sup> denotes a censored observation.

In patients treated with nivolumab in combination with chemotherapy, the incidence of pneumonitis including interstitial lung disease was 4.4% (80/1800). Grade 2, Grade 3, and Grade 4 cases were reported in 2.2% (40/1800), 0.9% (17/1800), and 0.2% (3/1800), of patients, respectively. Three patients (0.2%) had a fatal outcome. Median time to onset was 24.6 weeks (range: 0.6-96.9). Resolution occurred in 58 patients (72.5%) with a median time to resolution of 10.4 weeks (range: 0.3<sup>+</sup>-171.4<sup>+</sup>).

In patients treated with nivolumab 240 mg in combination with cabozantinib 40 mg in RCC the incidence of pneumonitis including interstitial lung disease was 5.6% (18/320). Grade 2 and Grade 3 cases were reported in 1.9% (6/320) and 1.6% (5/320), of patients, respectively. Median time to onset

was 26.9 weeks (range: 12.3-74.3 weeks). Resolution occurred in 14 patients (77.8%) with a median time to resolution of 7.5 weeks (range: 2.1-60.7<sup>+</sup> weeks).

#### Immune-related colitis

In patients treated with nivolumab monotherapy, the incidence of diarrhoea, colitis, or frequent bowel movements was 15.4% (716/4646). The majority of cases were Grade 1 or 2 in severity reported in 9.9% (462/4646) and 4.0% (186/4646) of patients respectively. Grade 3 and 4 cases were reported in 1.4% (67/4646) and <0.1% (1/4646) of patients respectively. Median time to onset was 8.3 weeks (range: 0.1-115.6). Resolution occurred in 639 patients (90.3%) with a median time to resolution of 2.9 weeks (range: 0.1-124.4<sup>+</sup>).

In patients treated with nivolumab in combination with chemotherapy, the incidence of diarrhoea or colitis was 22.5% (405/1800). Grade 2, Grade 3, and Grade 4 cases were reported in 7.2% (130/1800), 3.1% (56/1800), and 0.3% (6/1800) of patients, respectively. One patient (< 0.1%) had a fatal outcome. Median time to onset was 4.4 weeks (range: 0.1-93.6). Resolution occurred in 357 patients (88.6%) with a median time to resolution of 1.6 weeks (range: 0.1-212.3<sup>+</sup>).

In patients treated with nivolumab 240 mg in combination with cabozantinib 40 mg in RCC, the incidence of diarrhoea, colitis, frequent bowel movements or enteritis was 59.1% (189/320). Grade 2 and Grade 3 cases were reported in 25.6% (82/320) and 6.3% (20/320) of patients, respectively. Grade 4 were reported in 0.6% (2/320). Median time to onset was 12.9 weeks (range: 0.3-110.9-weeks). Resolution occurred in 143 patients (76.1%) with a median time to resolution of 12.9 weeks (range: 0.1-139.7<sup>+</sup> weeks).

#### Immune-related hepatitis

In patients treated with nivolumab monotherapy, the incidence of liver function test abnormalities was 8.0% (371/4646). Most cases were Grade 1 or 2 in severity reported in 4.3% (200/4646) and 1.8% (82/4646) of patients respectively. Grade 3 and 4 cases were reported in 1.6% (74/4646) and 0.3% (15/4646) of patients, respectively. Median time to onset was 10.6 weeks (range: 0.1-132.0). Resolution occurred in 298 patients (81.4%) with a median time to resolution of 6.1 weeks (range: 0.1-126.4<sup>+</sup>).

In patients treated with nivolumab in combination with chemotherapy, the incidence of liver function test abnormalities was 18% (322/1800). Grade 2, Grade 3 and Grade 4 cases were reported in 5.1% (92/1800), 2.6% (47/1800) and < 0.1% (1/1800) of patients, respectively. Median time to onset was 7.0 weeks (range: 0.1-99.0). Resolution occurred in 258 patients (81.1%) with a median time to resolution of 7.4 weeks (range: 0.4-240.0<sup>+</sup>).

In patients treated with nivolumab 240 mg in combination with cabozantinib 40 mg in RCC, the incidence of liver function test abnormalities was 41.6% (133/320). Grade 2, Grade 3, and Grade 4 cases were reported in 14.7% (47/320), 10.3% (33/320), and 0.6% (2/320) of patients, respectively. Median time to onset was 8.3 weeks (range: 0.1-107.9-weeks). Resolution occurred in 101 patients (75.9%) with a median time to resolution of 9.6 weeks (range: 0.1-89.3<sup>+</sup> weeks).

#### Immune-related nephritis and renal dysfunction

In patients treated with nivolumab monotherapy, the incidence of nephritis or renal dysfunction was 2.6% (121/4646). The majority of cases were Grade 1 or 2 in severity reported in 1.5% (69/4646) and 0.7% (32/4646) of patients respectively. Grade 3 and 4 cases were reported in 0.4% (18/4646) and <0.1% (2/4646) of patients, respectively. Median time to onset was 12.1 weeks (range: 0.1-79.1). Resolution occurred in 80 patients (69.0%) with a median time to resolution of 8.0 weeks (range: 0.3-79.1<sup>+</sup>).

In patients treated with nivolumab in combination with chemotherapy, the incidence of nephritis or renal dysfunction was 10.9% (196/1800). Grade 2, Grade 3, and Grade 4 cases were reported in 3.7% (66/1800), 1.4% (25/1800) and 0.2% (3/1800) of patients, respectively. Two patients (0.1%) had a fatal outcome. Median time to onset was 6.7 weeks (range: 0.1-60.7). Resolution occurred in 133 patients (67.9%) with a median time to resolution of 9.1 weeks (range: 0.1-226.0<sup>+</sup>).

In patients treated with nivolumab 240 mg in combination with cabozantinib 40 mg in RCC, the incidence of nephritis, immune mediated nephritis, renal failure, acute kidney injury, blood creatinine increased or blood urea increased was 10.0% (32/320). Grade 2 and Grade 3 cases were reported in 3.4% (11/320), and 1.3% (4/320) of patients, respectively. Median time to onset was 14.2 weeks (range: 2.1-87.1 weeks). Resolution occurred in 18 patients (58.1%) with a median time to resolution of 10.1 weeks (range: 0.6-90.9<sup>+</sup> weeks).

#### Immune-related endocrinopathies

In patients treated with nivolumab monotherapy, the incidence of thyroid disorders, including hypothyroidism or hyperthyroidism, was 13.0% (603/4646). The majority of cases were Grade 1 or 2 in severity reported in 6.6% (305/4646) and 6.2% (290/4646) of patients, respectively. Grade 3 thyroid disorders were reported in 0.2% (8/4646) of patients. Hypophysitis (3 Grade 1, 7 Grade 2, 9 Grade 3, and 1 Grade 4), hypopituitarism (6 Grade 2 and 1 Grade 3), adrenal insufficiency (including secondary adrenocortical insufficiency, adrenocortical insufficiency acute and blood corticotrophin decreased) (2 Grade 1, 23 Grade 2, and 11 Grade 3), diabetes mellitus (including Type 1 diabetes mellitus, and diabetic ketoacidosis) (1 Grade 1, 3 Grade 2 and 8 Grade 3 and 2 Grade 4), were reported. Median time to onset of these endocrinopathies was 11.1 weeks (range: 0.1-126.7). Resolution occurred in 323 patients (48.7%). Median time to resolution was 48.6 weeks (range: 0.4-204.4<sup>+</sup>).

In patients treated with nivolumab in combination with chemotherapy, the incidence of thyroid disorders was 12.8% (230/1800). Grade 2 and Grade 3 thyroid disorders were reported in 6.3% (114/1800) and 0.1% (2/1800) of patients, respectively. Grade 3 hypophysitis occurred in 0.1% (2/1800) of patients. Grade 2 and Grade 3 hypopituitarism occurred in 0.2% (4/1800) of patients, each. Grade 2, Grade 3 and Grade 4 adrenal insufficiency occurred in 0.6% (11/1800), 0.2% (3/1800) and <0.1% (1/1800) of patients, respectively. One patient (<0.1%) had a fatal outcome due to adrenal insufficiency. Diabetes mellitus including Type 1 diabetes mellitus, and fulminant Type 1 diabetes mellitus (4 Grade 2, 2 Grade 3 and 1 Grade 4), and diabetic ketoacidosis (1 Grade 2 and 1 Grade 4) were reported. Median time to onset of these endocrinopathies was 15.3 weeks (range: 1.1-124.3). Resolution occurred in 101 patients (40.1%). Time to resolution ranged from 0.3<sup>+</sup> to 233.6<sup>+</sup> weeks.

In patients treated with nivolumab 240 mg in combination with cabozantinib 40 mg in RCC, the incidence of thyroid disorders was 43.1% (138/320). Grade 2 and Grade 3 thyroid disorders were reported in 23.1% (74/320) and 0.9% (3/320) of patients, respectively. Hypophysitis occurred in 0.6% (2/320) of patients, all Grade 2. Adrenal insufficiency (including secondary adrenocortical insufficiency) occurred in 4.7% (15/320) of patients. Grade 2 and Grade 3 adrenal insufficiency cases were reported in 2.2% (7/320) and 1.9% (6/320) of patients, respectively. Median time to onset of these endocrinopathies was 12.3-weeks (range: 2.0-89.7-weeks). Resolution occurred in 50 patients (35.2%). Time to resolution ranged from 0.9 to 132.0<sup>+</sup> weeks.

#### Immune-related skin adverse reactions

In patients treated with nivolumab monotherapy, the incidence of rash was 30.0% (1396/4646). The majority of cases were Grade 1 in severity reported in 22.8% (1060/4646) of patients. Grade 2 and Grade 3 cases were reported in 5.9% (274/4646) and 1.3% (62/4646) of patients respectively. Median time to onset was 6.7 weeks (range: 0.1-121.1). Resolution occurred in 896 patients (64.6%) with a median time to resolution of 20.1 weeks (0.1-192.7<sup>+</sup>).

In patients treated with nivolumab in combination with chemotherapy, the incidence of rash was 25.4% (457/1800). Grade 2 and Grade 3 cases were reported in 6.2% (111/1800), and 2.3% (42/1800) of patients, respectively. Median time to onset was 6.4 weeks (range: 0.1-97.4). Resolution occurred in 320 patients (70.2%) with a median time to resolution of 12.1 weeks (range: 0.1-258.7<sup>+</sup>).

In patients treated with nivolumab 240 mg in combination with cabozantinib 40 mg in RCC, the incidence of rash was 62.8% (201/320). Grade 2 and Grade 3 cases were reported in 23.1% (74/320) and 10.6% (34/320) of patients, respectively. Median time to onset was 6.14 weeks (range: 0.1-104.4-weeks). Resolution occurred in 137 patients (68.2%) with a median time to resolution of 18.1 weeks (range: 0.1-130.6<sup>+</sup> weeks).

Rare cases of SJS and TEN some of them with fatal outcome have been observed (see sections 4.2 and 4.4).

#### Infusion reactions

In patients treated with nivolumab monotherapy, the incidence of hypersensitivity/infusion reactions was 4.0% (188/4646), including 9 Grade 3 and 3 Grade 4 cases.

In patients treated with nivolumab in combination with chemotherapy, the incidence of hypersensitivity/infusion reactions was 8.2% (148/1800). Grade 2, Grade 3, and Grade 4 cases were reported in 4.6% (83/1800), 1.1% (20/1800) and 0.2% (3/1800) of patients, respectively.

In patients treated with nivolumab 240 mg in combination with cabozantinib 40 mg in RCC, the incidence of hypersensitivity/infusion reactions was 2.5% (8/320). All 8 patients were Grade 1 or 2 in severity. Grade 2 cases were reported in 0.3% (1/320) of patients.

#### Elevated liver enzymes when nivolumab is combined with cabozantinib in RCC

In a clinical study of previously untreated patients with RCC receiving nivolumab in combination with cabozantinib, a higher incidence of Grades 3 and 4 ALT increased (10.1%) and AST increased (8.2%) were observed relative to nivolumab monotherapy in patients with advanced RCC. In patients with Grade  $\geq 2$  increased ALT or AST (n=85): median time to onset was 10.1 weeks (range: 2.0 to 106.6 weeks), 26% received corticosteroids for median duration of 1.4 weeks (range: 0.9 to 75.3 weeks), and resolution to Grades 0-1 occurred in 91% with median time to resolution of 2.3 weeks (range: 0.4 to 108.1<sup>+</sup> weeks). Among the 45 patients with Grade  $\geq 2$  increased ALT or AST who were rechallenged with either nivolumab (n=10) or cabozantinib (n=10) administered as a single agent or with both (n=25), recurrence of Grade  $\geq 2$  increased ALT or AST was observed in 3 patients receiving OPDIVO, 4 patients receiving cabozantinib, and 8 patients receiving both OPDIVO and cabozantinib.

#### Laboratory abnormalities

In patients treated with nivolumab monotherapy, the proportion of patients who experienced a shift from baseline to a Grade 3 or 4 laboratory abnormality was as follows: 3.4% for anaemia (all Grade 3), 0.7% for thrombocytopenia, 0.7% for leucopenia, 8.7% for lymphopenia, 0.9% for neutropenia, 1.7% for increased alkaline phosphatase, 2.6% for increased AST, 2.3% for increased ALT, 0.8% for increased total bilirubin, 0.7% for increased creatinine, 2.0% for hyperglycaemia, 0.7% for hypoglycaemia, 3.8% for increased amylase, 6.9% for increased lipase, 4.7% for hyponatraemia, 1.6% for hyperkalaemia, 1.3% for hypokalaemia, 1.1% for hypercalcaemia, 0.6% for hypermagnesaemia, 0.4% for hypomagnesaemia, 0.6% for hypocalcaemia, 0.6% for hypoalbuminaemia and <0.1% for hypernatraemia.

In patients treated with nivolumab in combination with chemotherapy, the proportion of patients who experienced a worsening from baseline to a Grade 3 or 4 laboratory abnormality was as follows: 14.7% for anaemia, 6.2% for thrombocytopenia, 11.7% leucopenia, 13.6% for lymphopenia, 26.3% neutropenia, 2.0% for increased alkaline phosphatase, 3.3% for increased AST, 2.6% for increased ALT, 1.9% for increased bilirubin, 1.3% for increased creatinine, 4.5% for increased amylase, 5.2% for increased lipase, 0.4% for hypernatraemia, 8.1% for hyponatraemia, 1.8% for hyperkalaemia, 5.1% for hypokalaemia, 0.7% for hypercalcaemia, 1.8% for hypocalcaemia, 1.5% for hypermagnesaemia, 2.9% for hypomagnesaemia, 3.7% for hyperglycaemia, and 0.6% for hypoglycaemia.

In patients treated with nivolumab 240 mg in combination with cabozantinib 40 mg in RCC, the proportion of patients who experienced a worsening from baseline to a Grade 3 or 4 laboratory abnormality was as follows: 3.5% for anaemia (all Grade 3), 0.3% for thrombocytopenia, 0.3% for leucopenia, 7.5% for lymphopenia, 3.5% for neutropenia, 3.2% for increased alkaline phosphatase, 8.2% for increased AST, 10.1% for increased ALT, 1.3% for increased total bilirubin, 1.3% for increased creatinine, 11.9% for increased amylase, 15.6% for increased lipase, 3.5% for hyperglycaemia, 0.8% for hypoglycaemia, 2.2% for hypocalcaemia, 0.3% for hypercalcaemia, 5.4%

for hyperkalaemia, 4.2% for hypermagnesaemia, 1.9% for hypomagnesaemia 3.2% for hypokalaemia, 12.3% for hyponatraemia, and 21.2% for hypophosphataemia.

#### Immunogenicity

Of the 3529 patients who were treated with nivolumab monotherapy 3 mg/kg or 240mg every 2 weeks and evaluable for the presence of anti-product-antibodies, 328 patients (9.3%) tested positive for treatment-emergent anti-product-antibodies with 21 patients (0.6%) testing positive for neutralising antibodies.

Co-administration with chemotherapy did not affect nivolumab immunogenicity. Of the 1407 patients who were treated with nivolumab 240 mg every 2 weeks or 360 mg every 3 weeks in combination with chemotherapy and evaluable for the presence of anti-product-antibodies, 7.2% tested positive for treatment emergent anti-product-antibodies with 0.5% tested positive for neutralising antibodies.

Although the clearance of nivolumab was increased by 20% when anti-nivolumab-antibodies were present, there was no evidence of loss of efficacy or altered toxicity profile in the presence of nivolumab antibodies based on the pharmacokinetic and exposure-response analyses for both monotherapy and combination.

#### Elderly

No overall differences in safety were reported between elderly ( $\geq 65$  years) and younger patients ( $< 65$  years). Data from NSCLC and adjuvant melanoma patients 75 years of age or older are too limited to draw conclusions on this population (see section 5.1).

For patients treated with nivolumab in combination with cabozantinib, data from RCC patients 75 years of age or older are too limited to draw conclusions on this population (see section 5.1).

#### Hepatic or renal impairment

In the non-squamous NSCLC study (CA209057), the safety profile in patients with baseline renal or hepatic impairment was comparable to that in the overall population. These results should be interpreted with caution due to the small sample size within the subgroups.

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.

## **4.9 Overdose**

No cases of overdose have been reported in clinical trials. In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions, and appropriate symptomatic treatment instituted immediately.

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies. ATC code: L01FF01.

#### Mechanism of action

Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody (HuMAb), which binds to the programmed death-1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. Engagement of PD-1 with the ligands PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment, results in inhibition of T-cell proliferation and cytokine secretion. Nivolumab

potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2 ligands. In syngeneic mouse models, blocking PD-1 activity resulted in decreased tumour growth.

### Clinical efficacy and safety

#### **Melanoma**

##### Treatment of advanced melanoma

###### Randomised phase 3 study vs. dacarbazine (CA209066)


The safety and efficacy of nivolumab 3 mg/kg for the treatment of advanced (unresectable or metastatic) melanoma were evaluated in a phase 3, randomised, double-blind study (CA209066). The study included adult patients (18 years or older) with confirmed, treatment-naïve, Stage III or IV BRAF wild-type melanoma and an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1. Patients with active autoimmune disease, ocular melanoma, or active brain or leptomeningeal metastases were excluded from the study.

A total of 418 patients were randomised to receive either nivolumab (n = 210) administered intravenously over 60 minutes at 3 mg/kg every 2 weeks or dacarbazine (n = 208) at 1000 mg/m<sup>2</sup> every 3 weeks. Randomisation was stratified by PD-L1 status and M stage (M0/M1a/M1b versus M1c). Treatment was continued as long as clinical benefit was observed or until treatment was no longer tolerated. Treatment after disease progression was permitted for patients who had a clinical benefit and did not have substantial adverse effects with the study drug, as determined by the investigator. Tumour assessments, according to the Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1, were conducted 9 weeks after randomisation and continued every 6 weeks for the first year and then every 12 weeks thereafter. The primary efficacy outcome measure was overall survival (OS). Key secondary efficacy outcome measures were investigator-assessed progression-free survival (PFS) and objective response rate (ORR).

Baseline characteristics were balanced between the two groups. The median age was 65 years (range: 18-87), 59% were men, and 99.5% were white. Most patients had ECOG performance score of 0 (64%) or 1 (34%). Sixty-one percent of patients had M1c stage disease at study entry. Seventy-four percent of patients had cutaneous melanoma, and 11% had mucosal melanoma; 35% of patients had PD-L1 positive melanoma ( $\geq 5\%$  tumour cell membrane expression). Sixteen percent of patients had received prior adjuvant therapy; the most common adjuvant treatment was interferon (9%). Four percent of patients had a history of brain metastasis, and 37% of patients had a baseline LDH level greater than ULN at study entry.

The Kaplan-Meier curves for OS are shown in Figure 1.

**Figure 1: Kaplan-Meier curves of OS (CA209066)**



Number of Subjects at Risk							
Nivolumab							
210	185	150	105	45	8	0	
Dacarbazine							
208	177	123	82	22	3	0	

—△— Nivolumab (events: 50/210), median and 95% CI: N.A.  
 ---○--- Dacarbazine (events: 96/208), median and 95% CI: 10.84 (9.33, 12.09)

The observed OS benefit was consistently demonstrated across subgroups of patients including baseline ECOG performance status, M stage, history of brain metastases, and baseline LDH level. Survival benefit was observed regardless of whether patients had tumours that were designated PD-L1 negative or PD-L1 positive (tumour membrane expression cut off of 5% or 10%).

Data available indicate that the onset of nivolumab effect is delayed such that benefit of nivolumab above chemotherapy may take 2-3 months.

Efficacy results are shown in Table 6.

**Table 6: Efficacy Results (CA209066)**

	<b>nivolumab (n = 210)</b>	<b>dacarbazine (n = 208)</b>
<b>Overall survival</b>		
Events	50 (23.8)	96 (46.2)
Hazard ratio		0.42
99.79% CI		(0.25, 0.73)
95% CI		(0.30, 0.60)
p-value		< 0.0001
Median (95% CI)	Not reached	10.8 (9.33, 12.09)
Rate (95% CI)		
At 6 months	84.1 (78.3, 88.5)	71.8 (64.9, 77.6)
At 12 months	72.9 (65.5, 78.9)	42.1 (33.0, 50.9)
<b>Progression-free survival</b>		
Events	108 (51.4)	163 (78.4)
Hazard ratio		0.43
95% CI		(0.34, 0.56)
p-value		< 0.0001
Median (95% CI)	5.1 (3.48, 10.81)	2.2 (2.10, 2.40)
Rate (95% CI)		
At 6 months	48.0 (40.8, 54.9)	18.5 (13.1, 24.6)
At 12 months	41.8 (34.0, 49.3)	NA
<b>Confirmed objective response</b>		
	84 (40.0%)	29 (13.9%)
(95% CI)	(33.3, 47.0)	(9.5, 19.4)
Odds ratio (95% CI)		4.06 (2.52, 6.54)
p-value		< 0.0001
Complete response (CR)	16 (7.6%)	2 (1.0%)
Partial response (PR)	68 (32.4%)	27 (13.0%)
Stable disease (SD)	35 (16.7%)	46 (22.1%)
<b>Median duration of response</b>		
Months (range)	Not reached (0 <sup>+</sup> - 12.5 <sup>+</sup> )	6.0 (1.1 - 10.0 <sup>+</sup> )
<b>Median time to response</b>		
Months (range)	2.1 (1.2 - 7.6)	2.1 (1.8 - 3.6)

“+” denotes a censored observation.

#### Randomised phase 3 study vs. chemotherapy (CA209037)

The safety and efficacy of nivolumab 3 mg/kg for the treatment of advanced (unresectable or metastatic) melanoma were evaluated in a phase 3, randomised, open-label study (CA209037). The study included adult patients who had progressed on or after ipilimumab and if BRAF V600 mutation positive had also progressed on or after BRAF kinase inhibitor therapy. Patients with active autoimmune disease, ocular melanoma or a known history of prior ipilimumab-related high-grade (Grade 4 per CTCAE v4.0) adverse reactions, except for resolved nausea, fatigue, infusion reactions, or endocrinopathies, were excluded from the study.

A total of 405 patients were randomised to receive either nivolumab (n = 272) administered intravenously over 60 minutes at 3 mg/kg every 2 weeks or chemotherapy (n = 133) which consisted of the investigator's choice of either dacarbazine (1000 mg/m<sup>2</sup> every 3 weeks) or carboplatin (AUC 6 every 3 weeks) and paclitaxel (175 mg/m<sup>2</sup> every 3 weeks). Randomisation was stratified by BRAF and PD-L1 status and best response to prior ipilimumab.

The co-primary efficacy outcome measures were confirmed ORR in the first 120 subjects treated with nivolumab, as measured by independent radiology review committee (IRRC) using RECIST 1.1, and comparison of OS of nivolumab to chemotherapy. Additional outcome measures included duration and timing of response.

The median age was 60 years (range: 23-88). Sixty-four percent of patients were men and 98% were white. ECOG performance scores were 0 for 61% of patients and 1 for 39% of patients. The majority (75%) of patients had M1c stage disease at study entry. Seventy-three percent of patients had cutaneous melanoma and 10% had mucosal melanoma. The number of prior systemic regimen received was 1 for 27% of patients, 2 for 51% of patients, and > 2 for 21% of patients. Twenty-two percent of patients had tumours that tested BRAF mutation positive and 50% of patients had tumours that were considered PD-L1 positive. Sixty-four percent of patients had no prior clinical benefit (CR/PR or SD) on ipilimumab. Baseline characteristics were balanced between groups except for the proportions of patients who had a history of brain metastasis (19% and 13% in the nivolumab group and chemotherapy group, respectively) and patients with LDH greater than ULN at baseline (51% and 35%, respectively).

At the time of this final ORR analysis, results from 120 nivolumab-treated patients and 47 chemotherapy-treated patients who had a minimum of 6 months of follow-up were analyzed. Efficacy results are presented in Table 7.

**Table 7: Best overall response, time and duration of response (CA209037)**

	<b>nivolumab (n = 120)</b>	<b>chemotherapy (n = 47)</b>
<b>Confirmed Objective Response (IRRC)</b>	38 (31.7%)	5 (10.6%)
(95% CI)	(23.5, 40.8)	(3.5, 23.1)
Complete Response (CR)	4 (3.3%)	0
Partial Response (PR)	34 (28.3%)	5 (10.6%)
Stable Disease (SD)	28 (23.3%)	16 (34.0%)
<b>Median Duration of Response</b>		
Months (range)	Not Reached	3.6 (Not available)
<b>Median Time to Response</b>		
Months (range)	2.1 (1.6-7.4)	3.5 (2.1-6.1)

Data available indicate that the onset of nivolumab effect is delayed such that benefit of nivolumab above chemotherapy may take 2-3 months.

#### Updated analysis (24-month follow-up)

Among all randomised patients, the ORR was 27.2% (95% CI: 22.0, 32.9) in the nivolumab group and 9.8% (95% CI: 5.3, 16.1) in the chemotherapy group. Median durations of response were 31.9 months (range: 1.4<sup>+</sup>-31.9) and 12.8 months (range: 1.3<sup>+</sup>-13.6<sup>+</sup>), respectively. The PFS HR for nivolumab vs. chemotherapy was 1.03 (95% CI: 0.78, 1.36). The ORR and PFS were assessed by IRRC per RECIST version 1.1.

There was no statistically significant difference between nivolumab and chemotherapy in the final OS analysis. The primary OS analysis was not adjusted to account for subsequent therapies, with 54 (40.6%) patients in the chemotherapy arm subsequently receiving an anti-PD1 treatment. OS may be confounded by dropout, imbalance of subsequent therapies and differences in baseline factors. More patients in the nivolumab arm had poor prognostic factors (elevated LDH and brain metastases) than in the chemotherapy arm.

*Efficacy by BRAF status:* Objective responses to nivolumab (according to the definition of the co-primary endpoint) were observed in patients with or without BRAF mutation-positive melanoma. The

ORRs in the BRAF mutation-positive subgroup were 17% (95% CI: 8.4, 29.0) for nivolumab and 11% (95% CI: 2.4, 29.2) for chemotherapy, and in the BRAF wild-type subgroup were 30% (95% CI: 24.0, 36.7) and 9% (95% CI: 4.6, 16.7), respectively.

The PFS HRs for nivolumab vs. chemotherapy were 1.58 (95% CI: 0.87, 2.87) for BRAF mutation-positive patients and 0.82 (95% CI: 0.60, 1.12) for BRAF wild-type patients. The OS HRs for nivolumab vs. chemotherapy were 1.32 (95% CI: 0.75, 2.32) for BRAF mutation-positive patients and 0.83 (95% CI: 0.62, 1.11) for BRAF wild-type patients.

*Efficacy by tumour PD-L1 expression:* Objective responses to nivolumab were observed regardless of tumour PD-L1 expression. However, the role of this biomarker (tumour PD-L1 expression) has not been fully elucidated.

In patients with tumour PD-L1 expression  $\geq 1\%$ , ORR was 33.5% for nivolumab (n=179; 95% CI: 26.7, 40.9) and 13.5% for chemotherapy (n=74; 95% CI: 6.7, 23.5). In patients with tumour PD-L1 expression  $< 1\%$ , ORR per IRRC was 13.0% (n=69; 95% CI: 6.1, 23.3) and 12.0% (n=25; 95% CI: 2.5, 31.2), respectively.

The PFS HRs for nivolumab vs. chemotherapy were 0.76 (95% CI: 0.54, 1.07) in patients with tumour PD-L1 expression  $\geq 1\%$  and 1.92 (95% CI: 1.05, 3.5) in patients with tumour PD-L1 expression  $< 1\%$ .

The OS HRs for nivolumab vs. chemotherapy were 0.69 (95% CI: 0.49, 0.96) in patients with tumour PD-L1 expression  $\geq 1\%$  and 1.52 (95% CI: 0.89, 2.57) in patients with tumour PD-L1 expression  $< 1\%$ .

These subgroup analyses should be interpreted with caution given the small size of the subgroups and lack of statistically significant difference in OS in the all randomised population.

#### Open-label phase 1 dose-escalation study (MDX1106-03)

The safety and tolerability of nivolumab were investigated in a phase 1, open-label dose-escalation study in various tumour types, including malignant melanoma. Of the 306 previously treated patients enrolled in the study, 107 had melanoma and received nivolumab at a dose of 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg for a maximum of 2 years. In this patient population, objective response was reported in 33 patients (31%) with a median duration of response of 22.9 months (95% CI: 17.0, NR). The median PFS was 3.7 months (95% CI: 1.9, 9.3). The median OS was 17.3 months (95% CI: 12.5, 37.8), and the estimated OS rates were 42% (95% CI: 32, 51) at 3 years, 35% (95% CI: 26, 44) at 4 years, and 34% (95% CI: 25, 43) at 5 years (minimum follow-up of 45 months).

#### Adjuvant treatment of melanoma

##### Randomised phase 3 study of nivolumab vs ipilimumab 10 mg/kg (CA209238)

The safety and efficacy of nivolumab 3 mg/kg as a single agent for the treatment of patients with completely resected melanoma were evaluated in a phase 3, randomised, double-blind study (CA209238). The study included adult patients, who had an ECOG performance status score of 0 or 1, with Stage IIIB/C or Stage IV American Joint Committee on Cancer (AJCC), 7<sup>th</sup> edition, histologically confirmed melanoma that is completely surgically resected. Per the AJCC 8<sup>th</sup> edition, this corresponds to patients with lymph node involvement or metastases. Patients were enrolled regardless of their tumour PD-L1 status. Patients with prior autoimmune disease, and any condition requiring systemic treatment with either corticosteroids ( $\geq 10$  mg daily prednisone or equivalent) or other immunosuppressive medications, as well as patients with prior therapy for melanoma (except patients with surgery, adjuvant radiotherapy after neurosurgical resection for lesions of the central nervous system, and prior adjuvant interferon completed  $\geq 6$  months prior to randomisation) prior therapy with, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways), were excluded from the study.

A total of 906 patients were randomised to receive either nivolumab 3 mg/kg (n = 453) administered every 2 weeks or ipilimumab 10 mg/kg (n = 453) administered every 3 weeks for 4 doses then every 12 weeks beginning at week 24 for up to 1 year. Randomisation was stratified by tumour PD-L1 expression ( $\geq 5\%$  vs.  $< 5\%$ /indeterminate), and stage of disease per the AJCC staging system. Tumour assessments were conducted every 12 weeks for the first 2 years then every 6 months thereafter. The primary endpoint was recurrence-free survival (RFS). RFS, assessed by investigator, was defined as the time between the date of randomisation and the date of first recurrence (local, regional, or distant metastasis), new primary melanoma, or death due to any cause, whichever occurred first.

Baseline characteristics were generally balanced between the two groups. The median age was 55 years (range: 18-86), 58% were men, and 95% were white. Baseline ECOG performance status score was 0 (90%) or 1 (10%). The majority of patients had AJCC Stage III disease (81%), and 19% had Stage IV disease. Forty-eight percent of patients had macroscopic lymph nodes and 32% had tumour ulceration. Forty-two percent of patients were BRAF V600 mutation positive while 45% were BRAF wild type and 13% BRAF were status unknown. For tumour PD-L1 expression, 34% of patients had PD-L1 expression  $\geq 5\%$  and 62% had  $< 5\%$  as determined by clinical trial assay. Among patients with quantifiable tumour PD-L1 expression, the distribution of patients was balanced across the treatment groups. Tumour PD-L1 expression was determined using the PD-L1 IHC 28-8 pharmDx assay.

Minimum follow-up was approximately 24 months. OS was not mature at the time of this analysis. RFS results are shown in Table 8 and Figure 2 (all randomised population).


**Table 8: Efficacy results (CA209238)**

	<b>nivolumab (n = 453)</b>		<b>ipilimumab 10 mg/kg (n = 453)</b>
<b>Recurrence-free survival</b>			
Events	171 (37.7%)		221 (48.8%)
Hazard ratio <sup>a</sup>		0.66	
95% CI		(0.54, 0.81)	
p-value		p<0.0001	
Median (95% CI) months	Not Available <sup>b</sup>		24.08 (16.56, NR)
Rate (95% CI) at 12 months	70.4 (65.9, 74.4)		60.0 (55.2, 64.5)
Rate (95% CI) at 18 months	65.8 (61.2, 70.0)		53.0 (48.1, 57.6)
Rate (95% CI) at 24 months	62.6 (57.9, 67.0)		50.2 (45.3, 54.8)

<sup>a</sup> Derived from a stratified proportional hazards model.

<sup>b</sup> Not available as median unstable due to low number of patients and censoring with 24 months of follow-up

**Figure 2: Recurrence-free survival (CA209238)**



Number of subjects at risk

Nivolumab

453 394 353 331 311 291 280 264 205 28 7 0

Ipilimumab

453 363 314 270 251 230 216 204 149 23 5 0

---Δ--- Nivolumab —○— Ipilimumab

The trial demonstrated a statistically significant improvement in RFS for patients randomised to the nivolumab arm compared with the ipilimumab 10 mg/kg arm. RFS benefit was consistently demonstrated across subgroups, including tumour PD-L1 expression, BRAF status, and stage of disease.

Quality of life (QoL) with nivolumab remained stable and close to baseline values during treatment, as assessed by valid and reliable scales like the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and the EQ-5D utility index and visual analog scale (VAS).

## Non-small Cell Lung Cancer (NSCLC)

### Squamous NSCLC

#### Randomised phase 3 study vs. docetaxel (CA209017)

The safety and efficacy of nivolumab 3 mg/kg as a single agent for the treatment of advanced or metastatic squamous NSCLC were evaluated in a phase 3, randomised, open-label study (CA209017). The study included patients (18 years or older) who have experienced disease progression during or after one prior platinum doublet-based chemotherapy regimen and an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. Patients were enrolled regardless of their PD-L1 status. Patients with active autoimmune disease, symptomatic interstitial lung disease, or untreated


brain metastasis were excluded from the study. Patients with treated brain metastases were eligible if neurologically returned to baseline at least 2 weeks prior to enrolment, and either off corticosteroids, or on a stable or decreasing dose of <10 mg daily prednisone equivalents.

A total of 272 patients were randomised to receive either nivolumab 3 mg/kg (N = 135) administered intravenously over 60 minutes every 2 weeks or docetaxel (n = 137) 75 mg/m<sup>2</sup> every 3 weeks. Treatment was continued as long as clinical benefit was observed or until treatment was no longer tolerated. Tumour assessments, according to the Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1, were conducted 9 weeks after randomisation and continued every 6 weeks thereafter. The primary efficacy outcome measure was overall survival (OS). Key secondary efficacy outcome measures were investigator-assessed objective response rate (ORR) and progression-free survival (PFS). In addition, symptom improvement and overall health status were assessed using the Lung Cancer Symptom Score (LCSS) average symptom burden index and the EQ-5D Visual Analogue Scale (EQ-VAS), respectively.

Baseline characteristics were generally balanced between the two groups. The median age was 63 years (range: 39-85) with 44% ≥65 years of age and 11% ≥75 years of age. The majority of patients were white (93%) and male (76%). Thirty-one percent had progressive disease reported as the best response to their most recent prior regimen and 45% received nivolumab within 3 months of completing their most recent prior regimen. Baseline ECOG performance status score was 0 (24%) or 1 (76%).

The Kaplan-Meier curves for OS are shown in Figure 3.

**Figure 3: Kaplan-Meier curves of OS (CA209017)**



		Overall Survival (Months)							
Number of Subjects at Risk									
Nivolumab 3 mg/kg	135	113	86	69	52	31	15	7	0
Docetaxel	137	103	68	45	30	14	7	2	0

—△— Nivolumab 3 mg/kg (events: 86/135), median and 95% CI: 9.23 (7.33, 13.27)  
 --⊖-- Docetaxel (events: 113/137), median and 95% CI: 6.01 (5.13, 7.33)

The observed OS benefit was consistently demonstrated across subgroups of patients. Survival benefit was observed regardless of whether patients had tumours that were designated PD-L1 negative or PD-L1 positive (tumour membrane expression cut off of 1%, 5% or 10%). However, the role of this biomarker (PD-L1 expression) has not been fully elucidated. With a minimum of 24.2 months follow up, OS benefit remains consistently demonstrated across subgroups.

Study CA209017 included a limited number of patients  $\geq 75$  years (11 in the nivolumab group and 18 in the docetaxel group). Nivolumab showed numerically less effect on OS (HR 1.85; 95% CI: 0.76, 4.51), PFS (HR=1.76; 95%-CI: 0.77, 4.05) and ORR (9.1% vs. 16.7%). Because of the small sample size, no definitive conclusions can be drawn from these data.

Efficacy results are shown in Table 9.

**Table 9: Efficacy results (CA209017)**

	<b>nivolumab (n = 135)</b>	<b>docetaxel (n = 137)</b>
<b>Primary analysis</b>		
Minimum follow-up: 10.6 months		
<b>Overall survival</b>		
Events	86 (63.7)	113 (82.5)
Hazard ratio		0.59
96.85% CI		(0.43, 0.81)
p-value		0.0002
Median (95% CI) months	9.23 (7.33, 13.27)	6.01 (5.13, 7.33)
Rate (95% CI) at 12 months	42.1 (33.7, 50.3)	23.7 (16.9, 31.1)
<b>Confirmed objective response</b>		
(95% CI)	27 (20.0%) (13.6, 27.7)	12 (8.8%) (4.6, 14.8)
Odds ratio (95% CI)		2.64 (1.27, 5.49)
p-value		0.0083
Complete response (CR)	1 (0.7%)	0
Partial response (PR)	26 (19.3%)	12 (8.8%)
Stable disease (SD)	39 (28.9%)	47 (34.3%)
<b>Median duration of response</b>		
Months (range)	Not reached (2.9 - 20.5 <sup>+</sup> )	8.4 (1.4 <sup>+</sup> - 15.2 <sup>+</sup> )
<b>Median time to response</b>		
Months (range)	2.2 (1.6 - 11.8)	2.1 (1.8 - 9.5)
<b>Progression-free survival</b>		
Events	105 (77.8)	122 (89.1)
Hazard ratio		0.62
95% CI		(0.47, 0.81)
p-value		< 0.0004
Median (95% CI) (months)	3.48 (2.14, 4.86)	2.83 (2.10, 3.52)
Rate (95% CI) at 12 months	20.8 (14.0, 28.4)	6.4 (2.9, 11.8)
<b>Updated analysis</b>		
Minimum follow-up: 24.2 months		
<b>Overall survival<sup>a</sup></b>		
Events	110 (81.4%)	128 (93.4%)
Hazard ratio		0.62
95% CI		(0.47, 0.80)
Rate (95% CI) at 24 months	22.9 (16.2, 30.3)	8 (4.3, 13.3)
<b>Confirmed objective response</b>		
(95% CI)	20.0% (13.6, 27.7)	8.8% (4.6, 14.8)
<b>Median duration of response</b>		
Months (range)	25.2 (2.9-30.4)	8.4 (1.4 <sup>+</sup> -18.0 <sup>+</sup> )
<b>Progression-free survival</b>		
Rate (95% CI) at 24 months	15.6 (9.7, 22.7)	All patients had either progressed, were censored, or lost to follow-up

**Updated analysis**

Minimum follow-up: 62.6 months

<b>Overall survival<sup>a</sup></b>		
Events	118 (87.4%)	133 (97.1%)
Hazard ratio		0.62
95% CI		(0.48, 0.79)
Rate (95% CI) at 60 months	12.3 (7.4, 18.5)	3.6 (1.4, 7.8)
<b>Confirmed objective response</b>		
(95% CI)	20.0% (13.6, 27.7)	8.8% (4.6, 14.8)
<b>Median duration of response</b>		
Months (range)	25.2 (2.9-70.6+)	7.5 (0.0+-18.0+)
<b>Progression-free survival</b>		
Rate (95% CI) at 60 months	9.4 (4.8, 15.8)	All patients had either progressed, were censored, or lost to follow-up

<sup>a</sup> Six patients (4%) randomised to docetaxel crossed over at any time to receive nivolumab treatment.

“+” Denotes a censored observation.

The rate of disease-related symptom improvement, as measured by LCSS, was similar between the nivolumab group (18.5%) and the docetaxel group (21.2%). The average EQ-VAS increased over time for both treatment groups, indicating better overall health status for patients remaining on treatment.

#### Single-arm phase 2 study (CA209063)

Study CA209063 was a single-arm, open-label study conducted in 117 patients with locally advanced or metastatic squamous-NSCLC after two or more lines of therapy; otherwise similar inclusion criteria as study CA209017 were applied. Nivolumab 3 mg/kg showed an overall response rate of 14.5% (95% CI: 8.7-22.2%), a median OS of 8.21 months (95% CI: 6.05-10.9 months), and a median PFS of 1.87 months (95% CI 1.77-3.15 months). The PFS was measured by RECIST version 1.1. The estimated 1-year survival rate was 41%.

#### Non-squamous NSCLC

##### Randomized phase 3 study vs. docetaxel (CA209057)

The safety and efficacy of nivolumab 3 mg/kg as a single agent for the treatment of advanced or metastatic non-squamous NSCLC were evaluated in a phase 3, randomized, open-label study (CA209057). The study included patients (18 years or older) who have experienced disease progression during or after one prior platinum doublet-based chemotherapy regimen which may have included maintenance therapy and who had an ECOG performance status score of 0 or 1. An additional line of TKI therapy was allowed for patients with known EGFR mutation or ALK translocation. Patients were enrolled regardless of their PD-L1 status. Patients with active autoimmune disease, symptomatic interstitial lung disease, or active brain metastasis were excluded from the study. Patients with treated brain metastases were eligible if neurologically returned to baseline at least 2 weeks prior to enrolment, and either off corticosteroids, or on a stable or decreasing dose of <10 mg daily prednisone equivalents.


A total of 582 patients were randomized to receive either nivolumab 3 mg/kg administered intravenously over 60 minutes every 2 weeks (n = 292) or docetaxel 75 mg/m<sup>2</sup> every 3 weeks (n = 290). Treatment was continued as long as clinical benefit was observed or until treatment was no longer tolerated. Tumour assessments, according to RECIST, version 1.1. The primary efficacy outcome measure was overall survival (OS). Key secondary efficacy outcome measures were investigator-assessed ORR and PFS. Additional prespecified subgroup analyses were conducted to evaluate the efficacy of tumour PD-L1 expression at predefined levels of 1%, 5% and 10%. Assessment according to discrete PD-L1 expression intervals were not included in the prespecified analyses due to the small sample sizes within the intervals.

Pre-study tumour tissue specimens were systematically collected prior to randomisation in order to conduct pre-planned analyses of efficacy according to tumour PD-L1 expression. Tumour PD-L1 expression was determined using the PD-L1 IHC 28-8 pharmDx assay.

The median age was 62 years (range: 21 to 85) with 34% ≥65 years of age and 7% ≥75 years of age. The majority of patients were white (92%) and male (55%). Baseline ECOG performance status was 0 (31%) or 1 (69%). Seventy-nine percent of patients were former/current smokers.

The Kaplan-Meier curves for OS are shown in Figure 4.

**Figure 4: Kaplan-Meier curves of OS (CA209057)**



—△— Nivolumab 3 mg/kg (events: 190/292), median and 95% CI: 12.19 (9.66, 14.98)  
 ---○--- Docetaxel (events: 223/290), median and 95% CI: 9.36 (8.05, 10.68)

The trial demonstrated a statistically significant improvement in OS for patients randomized to nivolumab as compared with docetaxel at the prespecified interim analysis when 413 events were observed (93% of the planned number of events for final analysis). Efficacy results are shown in Table 10.

**Table 10: Efficacy Results (CA209057)**

	<b>nivolumab (n = 292)</b>	<b>docetaxel (n = 290)</b>
<b>Prespecified interim analysis</b>		
Minimum follow-up: 13.2 months		
<b>Prespecified interim analysis</b>		
<b>Overall survival</b>		
Events (%)	190 (65.1%)	223 (76.9%)
Hazard ratio <sup>a</sup> (95.92% CI)		0.73 (0.59, 0.89)
p-value <sup>b</sup>		0.0015
Median (95% CI) months	12.19 (9.66, 14.98)	9.36 (8.05, 10.68)
Rate (95% CI) at 12 months	50.5 (44.6, 56.1)	39.0 (33.3, 44.6)
<b>Confirmed objective response</b>		
(95% CI)	56 (19.2%) (14.8, 24.2)	36 (12.4%) (8.8, 16.8)
Odds ratio (95% CI)		1.68 (1.07, 2.64)
p-value		0.0246
Complete response (CR)	4 (1.4%)	1 (0.3%)
Partial response (PR)	52 (17.8%)	35 (12.1%)
Stable disease (SD)	74 (25.3%)	122 (42.1%)
<b>Median duration of response</b>		
Months (range)	17.15 (1.8, 22.6+)	5.55 (1.2+, 15.2+)
<b>Median time to response</b>		
Months (range)	2.10 (1.2, 8.6)	2.61 (1.4, 6.3)
<b>Progression-free survival</b>		
Events	234 (80.1%)	245 (84.5%)
Hazard ratio 95% CI		0.92 (0.77, 1.11)
p-value		0.3932
Median (95% CI) (months)	2.33 (2.17, 3.32)	4.21 (3.45, 4.86)
Rate (95% CI) at 12 months	18.5 (14.1, 23.4)	8.1 (5.1, 12.0)
<b>Updated analysis</b>		
Minimum follow-up: 24.2 months		
<b>Overall survival<sup>c</sup></b>		
Events	228 (78.1%)	247 (85.1%)
Hazard ratio <sup>a</sup> (95% CI)		0.75 (0.63, 0.91)
Rate (95% CI) at 24 months	28.7 (23.6, 34.0)	15.8 (11.9, 20.3)
<b>Confirmed objective response</b>		
(95% CI)	19.2% (14.8, 24.2)	12.4% (8.8, 16.8)
<b>Median duration of response</b>		
Months (range)	17.2 (1.8-33.7 <sup>+</sup> )	5.6 (1.2 <sup>+</sup> -16.8)
<b>Progression-free survival</b>		
Rate (95% CI) at 24 months	11.9 (8.3, 16.2)	1.0 (0.2, 3.3)
<b>Updated analysis</b>		
Minimum follow-up: 62.7 months		
<b>Overall survival<sup>d</sup></b>		
Events	250 (85.6%)	279 (96.2%)
Hazard ratio <sup>a</sup>		0.70

(95% CI)		(0.58, 0.83)
Rate (95% CI) at 60 months	14.0 (10.2, 18.3)	2.1 (0.9, 4.4)
<b>Confirmed objective response</b>	19.5%	12.4%
(95% CI)	(15.1, 24.5)	(8.8, 16.8)
<b>Median duration of response</b>		
Months (range)	17.2 (1.8-70.4 <sup>+</sup> )	5.6 (0.0 <sup>+</sup> -33.4)
<b>Progression-free survival</b>		
Rate (95% CI) at 60 months	7.5 (4.5, 11.4)	All patients had either progressed, were censored, or lost to follow-up

<sup>a</sup> Derived from a stratified proportional hazards model.

<sup>b</sup> P-value is derived from a log-rank test stratified by prior maintenance therapy and line of therapy; the corresponding O'Brien-Fleming efficacy boundary significance level is 0.0408.

<sup>c</sup> Sixteen patients (6%) randomised to docetaxel crossed over at any time to receive nivolumab treatment.

<sup>d</sup> Seventeen patients (6%) randomised to docetaxel crossed over at any time to receive nivolumab treatment.

“+” Denotes a censored observation.

Quantifiable tumour PD-L1 expression was measured in 79% of patients in the nivolumab group and 77% of patients in the docetaxel group.

Tumour PD-L1 expression levels were balanced between the two treatment groups (nivolumab vs docetaxel) at each of the predefined PD-L1 expression levels of  $\geq 1\%$  (53% vs 55%),  $\geq 5\%$  (41% vs 38%), or  $\geq 10\%$  (37% vs 35%).

Patients with tumour PD-L1 expression by all predefined expression levels in the nivolumab group demonstrated greater likelihood of enhanced survival compared to docetaxel, whereas survival was similar to docetaxel in patients with no PD-L1 expression. In terms of ORR, increasing PD-L1 expression was associated with larger ORR. Comparable to the overall population, median duration of response was increased with nivolumab vs. docetaxel for patients with no PD-L1 expression (18.3 months vs. 5.6 months) and for patients with PD-L1 expression (16.0 months vs. 5.6 months).

Table 11 summarises results of ORR and OS by tumour PD-L1 expression.

**Table 11: ORR and OS by tumour PD-L1 expression (CA209057)**

<b>PD-L1 Expression</b>	<b>nivolumab</b>	<b>docetaxel</b>	
<b>ORR by tumour PD-L1 expression</b>			
Minimum follow-up: 13.2 months			
			<b>Odds Ratio (95% CI)</b>
< 1%	10/108 (9.3%) 95% CI: 4.5, 16.4	15/101 (14.9%) 95% CI: 8.6, 23.3	0.59 (0.22, 1.48)
≥ 1%	38/123 (30.9%) 95% CI: 22.9, 39.9	15/123 (12.2%) 95% CI: 7.0, 19.3	3.22 (1.60, 6.71)
≥ 1% to < 10% <sup>a</sup>	6/37 (16.2%) 95% CI: 6.2, 32.0	5/44 (11.4%) 95% CI: 3.8, 24.6	1.51 (0.35, 6.85)
≥ 10% to < 50% <sup>a</sup>	5/20 (25.0%) 95% CI: 8.7, 49.1	7/33 (21.2%) 95% CI: 9.0, 38.9	1.24 (0.26, 5.48)
≥ 50% <sup>a</sup>	27/66 (40.9%) 95% CI: 29.0, 53.7	3/46 (6.5%) 95% CI: 1.4, 17.9	9.92 (2.68, 54.09)
<b>OS by tumour PD-L1 expression</b>			
Minimum follow-up: 13.2 months			
	<b>Number of events (number of patients)</b>		<b>Unstratified Hazard Ratio (95% CI)</b>
< 1%	77 (108)	75 (101)	0.90 (0.66, 1.24)
≥ 1%	68 (123)	93 (123)	0.59 (0.43, 0.82)
≥ 1% to < 10% <sup>a</sup>	27 (37)	30 (44)	1.33 (0.79, 2.24)
≥ 10% to < 50% <sup>a</sup>	11 (20)	26 (33)	0.61 (0.30, 1.23)
≥ 50% <sup>a</sup>	30 (66)	37 (46)	0.32 (0.20, 0.53)
<b>Updated analysis</b>			
Minimum follow-up: 24.2 months			
< 1%	91 (108)	86 (101)	0.91 (0.67, 1.22)
≥ 1%	87 (123)	103 (123)	0.62 (0.47, 0.83)
<b>Updated analysis</b>			
Minimum follow-up: 62.7 months			
< 1%	100 (109)	96 (101)	0.87 (0.66, 1.16)
≥ 1%	96 (122)	119 (123)	0.55 (0.42, 0.73)

<sup>a</sup> Post-hoc analysis; results should be interpreted with caution as the subgroup samples sizes are small and, at the time of the analysis, the PD-L1 IHC 28-8 pharmDx assay was not analytically validated at the 10% or 50% expression levels.

A higher proportion of patients experienced death within the first 3 months in the nivolumab arm (59/292, 20.2%) as compared to the docetaxel arm (44/290, 15.2%). Results of a post-hoc, exploratory multivariate analysis indicated that nivolumab-treated patients with poorer prognostic features and/or aggressive disease when combined with lower (e.g., < 50%) or no tumour PD-L1 expression may be at higher risk of death within the first 3 months.

In subgroup analyses, survival benefit compared to docetaxel was not shown for patients who were never-smokers or whose tumours harboured EGFR activating mutations; however, due to the small numbers of patients, no definitive conclusions can be drawn from these data.

### Neoadjuvant treatment of NSCLC

#### Randomised, open-label, phase 3 study of nivolumab in combination with platinum-based chemotherapy vs. platinum-based chemotherapy (CA209816)

The safety and efficacy of nivolumab in combination with platinum-based chemotherapy for 3 cycles were evaluated in a phase 3, randomised, open-label study (CA209816). The study included patients with ECOG performance status 0 or 1, measurable disease (per RECIST version 1.1), and whose tumours were resectable, histologically confirmed Stage IB ( $\geq 4$  cm), II, or IIIA NSCLC (per the 7<sup>th</sup> edition AJCC/Union for International Cancer Control (UICC) staging criteria). Patients were enrolled regardless of their tumour PD-L1 status. Patients with unresectable or metastatic NSCLC, known EGFR mutations or ALK translocations, Grade 2 or greater peripheral neuropathy, active autoimmune disease, or medical conditions requiring systemic immunosuppression were excluded from the study. Randomisation was stratified by tumour PD-L1 expression level ( $\geq 1\%$  vs  $< 1\%$  or non-quantifiable), disease stage (IB/II vs. IIIA), and gender (male vs. female).

A total of 358 patients were randomised to receive either nivolumab in combination with platinum-based chemotherapy (n = 179) or platinum-based chemotherapy (n = 179). Patients in the nivolumab in combination with chemotherapy arm received nivolumab 360 mg administered intravenously over 30 minutes in combination with platinum-based chemotherapy every 3 weeks for up to 3 cycles. Patients in the chemotherapy arm received platinum-based chemotherapy administered every 3 weeks for up to 3 cycles. Platinum-based chemotherapy consisted of investigator's choice of paclitaxel 175 mg/m<sup>2</sup> or 200 mg/m<sup>2</sup> and carboplatin AUC 5 or AUC 6 (any histology); pemetrexed 500 mg/m<sup>2</sup> and cisplatin 75 mg/m<sup>2</sup> (non-squamous histology); or gemcitabine 1000 mg/m<sup>2</sup> or 1250 mg/m<sup>2</sup> and cisplatin 75 mg/m<sup>2</sup> (squamous histology). In the chemotherapy arm, two additional treatment regimen options included vinorelbine 25 mg/m<sup>2</sup> or 30 mg/m<sup>2</sup> and cisplatin 75 mg/m<sup>2</sup>; or docetaxel 60 mg/m<sup>2</sup> or 75 mg/m<sup>2</sup> and cisplatin 75 mg/m<sup>2</sup> (any histology).

Tumour assessments were performed at baseline, within 14 days of surgery, every 12 weeks after surgery for 2 years, then every 6 months for 3 years, and every year for 5 years until disease recurrence or progression. The primary efficacy outcome measures were event free survival (EFS) based on BICR assessment and pathological complete response rate (pCR) by blinded-independent pathology review (BIPR). OS was a key secondary efficacy outcome measure and exploratory endpoints included feasibility of surgery. Baseline characteristics were generally balanced across treatment groups. The median age was 65 years (range: 34-84) with 51% of patients  $\geq 65$  years and 7% of patients  $\geq 75$  year; 50% of patients were Asian, 47% were white and 71% were male. Baseline ECOG performance status was 0 (67%) or 1 (33%); 50% of patients with PD-L1  $\geq 1\%$  and 43% with PD-L1  $< 1\%$ , 5% had Stage IB, 17% had Stage IIA, 13% had Stage IIB, and 64% had Stage IIIA disease; 51% had squamous and 49% had non-squamous histology; and 89% were former/current smokers.

Numerically more patients in the nivolumab in combination with chemotherapy arm (83%) had definitive surgery compared to patients in the chemotherapy arm (75%).

At the final pCR analysis and pre-specified interim EFS analysis (minimum follow-up 21 months), statistically significant improvement was demonstrated in pCR and EFS for patients randomised to nivolumab in combination with chemotherapy as compared to chemotherapy alone. Efficacy results are presented in Table 12 and Figure 5.

**Table 12: Efficacy results (CA209816)**

	<b>nivolumab + chemotherapy (n = 179)</b>	<b>chemotherapy (n = 179)</b>
<b>Event free survival per BICR</b>		
Events	64 (35.8%)	87 (48.6%)

**Table 12: Efficacy results (CA209816)**

	<b>nivolumab + chemotherapy (n = 179)</b>	<b>chemotherapy (n = 179)</b>
Hazard ratio <sup>a</sup> (97.38% CI)		0.63 (0.43, 0.91)
Stratified log-rank p-value <sup>b</sup>		0.0052
Median (months) <sup>c</sup> (95% CI)	31.6 (30.2, NR)	20.8 (14.0, 26.7)
Rate (95% CI) at 12 months	76.1 (68.8, 81.9)	63.4 (55.3, 70.4)
Rate (95% CI) at 24 months	63.8 (55.7, 70.9)	45.3 (37.0, 53.2)
<b>Pathologic complete response per BIPR</b>		
Responses	43 (24.0%)	4 (2.2%)
95% CI <sup>d</sup>	18.0, 31.0	0.6, 5.6
Difference of pCR (99% CI) <sup>e</sup>		21.6 (13.0, 30.3)
Odds ratio of pCR (99% CI) <sup>f</sup>		13.9 (3.49, 55.75)
Stratified p-value <sup>g</sup>		<0.0001

<sup>a</sup> Based on a stratified Cox proportional hazard model.

<sup>b</sup> Based on a stratified log-rank test. Boundary for statistical significance: p-value <0.0262.

<sup>c</sup> Kaplan-Meier estimate.

<sup>d</sup> Based on Clopper and Pearson method.

<sup>e</sup> Strata-adjusted difference based on Cochran-Mantel-Haenszel (CMH) method of weighting.


<sup>f</sup> Strata-adjusted using Mantel-Haenszel method.

<sup>g</sup> From stratified CMH test.

Minimum follow-up for EFS was 21 months, data cut-off 08-Sept-2021

pCR data cut-off: 28-Jul-2020

**Figure 5: Kaplan-Meier curves of EFS (CA209816)**



Number of Subjects at Risk														
Nivolumab + chemotherapy														
179	151	136	124	118	107	102	87	74	41	34	13	6	3	0
Chemotherapy														
179	144	126	109	94	83	75	61	52	26	24	13	11	4	0

—○— Nivolumab + chemotherapy (events: 64/179), median and 95% CI:31.6 (30.2, NR)

--△-- Chemotherapy (events: 87/179), median and 95% CI: 20.8 (14.0, 26.7)

Based on data cut-off: 08-Sept-2021, minimum follow-up of 21 months

In descriptive, exploratory analyses, EFS and pCR favoured nivolumab in combination with chemotherapy relative to chemotherapy across key subgroups (including PD-L1, disease stage, histology).

At the time of the EFS analysis, a prespecified, interim analysis for OS was performed. The HR for OS was 0.57 (99.67% CI: 0.30, 1.07) for nivolumab in combination with chemotherapy vs. chemotherapy.

#### Neoadjuvant and adjuvant treatment of NSCLC

##### Randomised, double-blind, phase 3 study of neoadjuvant nivolumab in combination with platinum-based chemotherapy vs. platinum-based chemotherapy and adjuvant nivolumab monotherapy vs. placebo (CA20977T)

The safety and efficacy of nivolumab in combination with platinum-based chemotherapy for 4 cycles, followed by nivolumab monotherapy, were evaluated in a randomised, double-blind study (CA20977T). The study included patients with ECOG performance status 0 or 1 whose tumours were resectable, suspected or histologically confirmed Stage IIA (> 4 cm) to IIIB (T3-T4 N2) NSCLC (per

the 8<sup>th</sup> edition American Joint Committee on Cancer (AJCC) Staging Manual). Patients were enrolled regardless of their tumour PD-L1 status.

The following selection criteria define patients with high risk of recurrence who are included in the therapeutic indication and are reflective of a patient population with stage IIA-III B disease according to the 8<sup>th</sup> edition AJCC/UICC staging criteria: any patient with a tumour size > 4 cm; any patient with N1 or N2 disease (regardless of primary tumour size); patients with multiple tumour nodules in either the same lobe or different ipsilateral lobes; patients with tumours that are invasive of thoracic structures (directly invade visceral pleura, parietal pleura, chest wall, diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, oesophagus, vertebral body, carina); or tumours that involve the main bronchus; or tumours that are associated with atelectasis or obstructive pneumonitis that extends to the hilar region or involves the entire lung.

Patients with unresectable or metastatic NSCLC, EGFR mutations or known ALK translocations (testing for ALK translocations was not mandatory at study entry), brain metastasis, Grade 2 or greater peripheral neuropathy, interstitial lung disease or active, non-infectious pneumonitis (symptomatic and/or requiring treatment), active autoimmune disease, or medical conditions requiring systemic immunosuppression were excluded from the study.

A total of 461 patients were randomised to receive either nivolumab in combination with platinum-based chemotherapy followed by nivolumab monotherapy (n=229) or platinum-based chemotherapy followed by placebo (n=232). In the neoadjuvant phase, patients received either nivolumab 360 mg administered intravenously over 30 minutes and platinum-doublet chemotherapy administered every 3 weeks, or placebo and platinum-doublet chemotherapy administered every 3 weeks until disease progression or unacceptable toxicity, for up to 4 cycles. Patients in both treatment arms could receive post-operative radiation therapy (PORT) as standard of care. In the adjuvant phase, within 90 days after the surgery patients received either nivolumab 480 mg administered intravenously over 30 minutes every 4 weeks, or placebo administered every 4 weeks for until disease progression, recurrence, or unacceptable toxicity, for up to 13 cycles. Platinum-based chemotherapy consisted of paclitaxel 175 mg/m<sup>2</sup> or 200 mg/m<sup>2</sup> and carboplatin AUC 5 or AUC 6 (any histology); pemetrexed 500 mg/m<sup>2</sup>, and cisplatin 75 mg/m<sup>2</sup> or carboplatin AUC 5 or AUC 6 (non-squamous histology); or cisplatin 75 mg/m<sup>2</sup> and docetaxel 75 mg/m<sup>2</sup> (squamous histology).

Stratification factors for randomisation were tumour PD-L1 expression level ( $\geq 1\%$  versus  $< 1\%$  versus indeterminate/not evaluable), disease stage (Stage II versus Stage III), and tumour histology (squamous versus nonsquamous). Tumour PD-L1 expression levels were assessed using the PD-L1 IHC 28-8 pharmDx test. Tumour assessments were performed at baseline, within 14 days after the last dose of neoadjuvant treatment and before surgery, within 7 days prior to the start of adjuvant treatment after surgery, every 12 weeks after the first dose of adjuvant treatment for 2 years, then every 24 weeks for up to 5 years until disease recurrence or progression was confirmed by BICR.

Among the 442 patients in CA20977T, 256 (58%) had tumour PD-L1 expression  $\geq 1\%$  based on the PD-L1 IHC 28-8 pharmDx test. The median age was 66 years (range: 35 to 86) with 55% of patients  $\geq 65$  years and 7% of patients  $\geq 75$  years, 69% were White, 28% were Asian, 2% were Black, and 75% were male. Baseline ECOG performance status was 0 (59%) or 1 (41%); 36% had stage II and 63% had stage III disease; 24% were N1 and 39% were N2; 25% were single-station and 14% were multistation; 61% had tumours with squamous histology and 39% had tumours with non-squamous histology; and 91% were former/current smokers.

Seventy-eight percent of patients in the neoadjuvant nivolumab in combination with platinum-doublet chemotherapy followed by adjuvant nivolumab arm had definitive surgery compared to 77% of patients in the neoadjuvant placebo and platinum-doublet chemotherapy followed by placebo arm. Approximately 5% of patients in each treatment arm received PORT.

The primary efficacy outcome measure was event-free survival (EFS) based on BICR assessment. Additional efficacy outcome measures included overall survival (OS), pathologic complete response (pCR) and major pathologic response as evaluated by blinded independent pathology review (BIPR).

In a pre-specified interim analysis in all randomised patients with a median follow-up of 25.4 months (range: 15.7-44.2 months), the study demonstrated statistically significant improvement of EFS. Median EFS was not reached (95% CI: 28.94, NE) in the nivolumab in combination with chemotherapy/nivolumab arm and 18.43 months (95% CI: 13.63, 28.06) in the placebo with chemotherapy/placebo arm (HR = 0.58, 97.36% CI: 0.42, 0.81; stratified log-rank p-value 0.00025). In a pre-specified interim analysis in all randomised patients with a median follow-up of 41 months (range: 31.3-59.8 months), median OS was not reached in both the nivolumab in combination with chemotherapy/nivolumab arm and in the placebo with chemotherapy/placebo arm (HR = 0.85, 97.63% CI: 0.58, 1.25).

*Exploratory subgroup analysis by tumour PD-L1 expression*


EFS for the subgroup of patients with tumour PD-L1 expression  $\geq 1\%$ , with a median follow-up of 41 months (range: 31.3-59.8 months), are presented in Table 13 and Figure 6.

**Table 13: Efficacy results in patients with tumour PD-L1  $\geq 1\%$  (CA20977T)**

	nivolumab with chemotherapy/ nivolumab (n=128)	placebo with chemotherapy/ placebo (n=128)
<b>Event-free survival (EFS) per BICR</b>		
Events (%)	47 (37%)	70 (55%)
Median (months) <sup>a</sup> (95% CI)	46.55 (35.81, NE)	15.08 (9.33, 31.41)
Hazard Ratio <sup>b</sup> (95% CI)	0.53 (0.36, 0.76)	

NE = non-estimable  
 Minimum follow-up for EFS was 31.3 months; data cut-off: 11-Nov-2024.  
<sup>a</sup> Kaplan-Meier estimate.  
<sup>b</sup> Based on an unstratified Cox proportional hazard model.

**Figure 6: Kaplan-Meier curves of EFS in patients with tumour PD-L1  $\geq 1\%$  (CA20977T)**



Event Free Survival per BICR (Months)

Number of Subjects at Risk

Nivolumab + chemotherapy/Nivolumab																				
128	119	95	89	83	80	78	75	73	70	61	55	44	35	17	11	2	1	1	1	0
Placebo + chemotherapy/Placebo																				
128	110	87	68	57	54	46	44	42	42	40	36	23	20	9	8	2	1	0	0	0


—△— Nivolumab + chemotherapy/Nivolumab (events: 47/128), median and 95% CI:46.55 (35.81, NE)

---○--- Placebo + Chemotherapy/Placebo (events: 70/128), median and 95% CI: 15.08 (9.33, 31.41)

Based on data cut-off 11-Nov-2024, minimum follow-up of 31.3 months

At the time of the updated EFS analysis, an interim analysis for OS was performed (minimum follow-up of 31.3 months). The exploratory, descriptive HR for OS in patients with tumour PD-L1 expression  $\geq 1\%$  was 0.61 (95% CI: 0.39, 0.97) for the nivolumab in combination with chemotherapy/nivolumab arm vs. the placebo with chemotherapy/placebo arm. The Kaplan-Meier curves for OS for the subgroup of patients with tumour PD-L1 expression  $\geq 1\%$  are shown in Figure 7.

**Figure 7: Kaplan-Meier curves of OS in patients with tumour PD-L1  $\geq 1\%$  (CA20977T)**



Number of Subjects at Risk

	0	3	6	9	12	15	18	21	24	27	30	33	36	39	42	45	48	51	54	57	60
Nivolumab + chemotherapy/Nivolumab	128	123	114	108	103	99	96	94	92	90	90	80	67	55	42	26	15	4	2	1	0
Placebo + chemotherapy/Placebo	128	126	116	106	101	96	88	86	77	77	73	65	54	36	25	17	10	5	4	0	0

—△— Nivolumab + chemotherapy/Nivolumab (events: 31/128), median and 95% CI: NR  
 ---○--- Placebo + Chemotherapy/Placebo (events: 46/128), median and 95% CI: NR (38.08, NE)

Based on data cut-off 11-Nov-2024, minimum follow-up of 31.3 months

### Renal Cell Carcinoma (RCC)

#### Randomised, open-labeled, phased 3 study vs. everolimus (CA209025)

The safety and efficacy of nivolumab 3mg/kg as a single agent for the treatment of advanced RCC was evaluated in a Phase 3, randomized, opened-label study (CA209025). The study included patients (18 years or older) who have experienced disease progression during or after 1 or 2 prior anti-angiogenic therapy regimens and no more than 3 total prior systemic treatment regimens. Patients had to have a Karnofsky Performance Score (KPS)  $\geq 70\%$ . This study included patients regardless of their PD-L1 status. Patients with any history of or concurrent brain metastases, prior treatment with a mammalian target of rapamycin (mTOR) inhibitor, active autoimmune disease, or medical conditions requiring systemic immunosuppression were excluded from the study.

A total of 821 patients were randomized to receive either nivolumab 3 mg/kg (n=410) administered intravenously over 60 minutes every 2 weeks or everolimus (n=411) 10 mg daily, administered orally. Treatment was continued as long as clinical benefit was observed or until treatment was no longer tolerated. The first tumour assessments were conducted 8 weeks after randomization and continued every 8 weeks thereafter for the first year and then every 12 weeks until progression or treatment discontinuation, whichever occurred later. Tumour assessments were continued after treatment discontinuation in patients who discontinued treatment for reasons other than progression. Treatment beyond initial investigator-assessed RECIST 1.1-defined progression was permitted if the patient had a clinical benefit and was tolerating study drug as determined by the investigator. The primary efficacy


outcome measure was OS. Secondary efficacy assessments included investigator-assessed ORR and PFS.

Baseline characteristics were generally balanced between the two groups. The median age was 62 years (range: 18-88) with 40% ≥65 years of age and 9% ≥75 years of age. The majority of patients were male (75%) and white (88%), all Memorial Sloan Kettering Cancer Center (MSKCC) risk groups were represented, and 34% and 66% of patients had a baseline KPS of 70% to 80% and 90% to 100%, respectively. The majority of patients (72%) were treated with one prior anti-angiogenic therapy. The median duration of time from initial diagnosis to randomization was 2.6 years in both the nivolumab and everolimus groups. The median duration of treatment was 5.5 months (range: 0- 29.6<sup>+</sup> months) in nivolumab-treated patients and was 3.7 months (range: 6 days-25.7<sup>+</sup> months) in everolimus-treated patients.

Nivolumab was continued beyond progression in 44% of patients.

The Kaplan-Meier curves for OS are shown in Figure 8.

**Figure 8: Kaplan-Meier curves of OS (CA209025)**



Number of Subjects at Risk		Overall Survival (Months)										
Nivolumab	410	389	359	337	305	275	213	139	73	29	3	0
Everolimus	411	366	324	287	265	241	187	115	61	20	2	0

—△— Nivolumab 3 mg/kg (events: 183/410), median and 95% CI: 25.00 (21.75, N.A.)  
 --○-- Everolimus 10 mg (events: 215/411), median and 95% CI: 19.55 (17.64, 23.06)

The trial demonstrated a statistically significant improvement in OS for patients randomized to nivolumab as compared with everolimus at the prespecified interim analysis when 398 events were observed (70% of the planned number of events for final analysis) (Table 14 and Figure 8). OS benefit was observed regardless of PD-L1 expression level.

Efficacy results are shown in Table 14.

**Table 14: Efficacy results (CA209025)**

	<b>nivolumab (n = 410)</b>		<b>everolimus (n = 411)</b>
<b>Overall survival</b>			
Events	183 (45)		215 (52)
Hazard ratio		0.73	
98.52% CI		(0.57, 0.93)	
p-value		0.0018	
Median (95% CI)	25.0 (21.7, NE)		19.6 (17.6, 23.1)
Rate (95% CI)			
At 6 months	89.2 (85.7, 91.8)		81.2 (77.0, 84.7)
At 12 months	76.0 (71.5, 79.9)		66.7 (61.8, 71.0)
<b>Objective response</b>			
(95% CI)	103 (25.1%) (21.0, 29.6)		22 (5.4%) (3.4, 8.0)
Odds ratio (95% CI)		5.98 (3.68, 9.72)	
p-value		< 0.0001	
Complete response (CR)	4 (1.0%)		2 (0.5%)
Partial response (PR)	99 (24.1%)		20 (4.9%)
Stable disease (SD)	141 (34.4%)		227 (55.2%)
<b>Median duration of response</b>			
Months (range)	11.99 (0.0-27.6 <sup>+</sup> )		11.99 (0.0 <sup>+</sup> -22.2 <sup>+</sup> )
<b>Median time to response</b>			
Months (range)	3.5 (1.4-24.8)		3.7 (1.5-11.2)
<b>Progression-free survival</b>			
Events	318 (77.6)		322 (78.3)
Hazard ratio		0.88	
95% CI		(0.75, 1.03)	
p-value		0.1135	
Median (95% CI)	4.6 (3.71, 5.39)		4.4 (3.71, 5.52)

“+” denotes a censored observation.

NE = non-estimable

The median time to onset of objective response was 3.5 months (range: 1.4-24.8 months) after the start of nivolumab treatment. Forty-nine (47.6%) responders had ongoing responses with a duration ranging from 0.0-27.6<sup>+</sup> months.

Overall survival could be accompanied by an improvement over time in disease related symptoms and non-disease specific QoL as assessed using valid and reliable scales in the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) and the EuroQoL EQ-5D. Apparently meaningful symptom improvement (MID = 2 point change in FKSI-DRS score;

$p < 0.001$ ) and time to improvement (HR = 1.66 (1.33,2.08),  $p < 0.001$ ) were significantly better for patients on the nivolumab arm. While both arms of the study received active therapy, the QoL data should be interpreted in the context of the open-label study design and therefore cautiously taken.

*Randomised phase 3 study of nivolumab in combination with cabozantinib vs. sunitinib (CA2099ER)*

The safety and efficacy of nivolumab 240 mg in combination with cabozantinib 40 mg for the first-line treatment of advanced/metastatic RCC was evaluated in a phase 3, randomised, open-label study (CA2099ER). The study included patients (18 years or older) with advanced or metastatic RCC with a clear cell component, Karnofsky Performance Status (KPS)  $\geq 70\%$ , and measurable disease as per RECIST v1.1 regardless of their PD-L1 status or IMDC risk group. The study excluded patients with autoimmune disease or other medical conditions requiring systemic immunosuppression, patients who had prior treatment with an anti-PD-1, anti PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, poorly controlled hypertension despite antihypertensive therapy, active brain metastases and uncontrolled adrenal insufficiency. Patients were stratified by IMDC prognostic score, PD-L1 tumour expression, and region.

A total of 651 patients were randomised to receive either nivolumab 240 mg ( $n = 323$ ) administered intravenously every 2 weeks in combination with cabozantinib 40 mg once daily orally or sunitinib ( $n = 328$ ) 50 mg daily, administered orally for 4 weeks followed by 2 weeks off. Treatment continued until disease progression or unacceptable toxicity with nivolumab administration for up to 24 months. Treatment beyond initial investigator-assessed RECIST version 1.1-defined progression was permitted if the patient had a clinical benefit and was tolerating study drug, as determined by the investigator. First tumour assessment post-baseline was performed at 12 weeks ( $\pm 7$  days) following randomisation. Subsequent tumour assessments occurred at every 6 weeks ( $\pm 7$  days) until Week 60, then every 12 weeks ( $\pm 14$  days) until radiographic progression, confirmed by the BICR. The primary efficacy outcome measure was PFS as determined by a BICR. Additional efficacy measures included OS and ORR as key secondary endpoints.

Baseline characteristics were generally balanced between the two groups. The median age was 61 years (range: 28-90) with 38.4%  $\geq 65$  years of age and 9.5%  $\geq 75$  years of age. The majority of patients were male (73.9%) and white (81.9%). Eight percent of patients were Asian, 23.2% and 76.5% of patients had a baseline KPS of 70 to 80% and 90 to 100%, respectively. Patient distribution by IMDC risk categories was 22.6% favourable, 57.6% intermediate, and 19.7% poor. For tumour PD-L1 expression, 72.5% of patients had PD-L1 expression  $< 1\%$  or indeterminate and 24.9% of patients had PD-L1 expression  $\geq 1\%$ . 11.5% of patients had tumours with sarcomatoid features. The median duration of treatment was 14.26 months (range: 0.2-27.3 months) in nivolumab with cabozantinib-treated patients and was 9.23 months (range: 0.8-27.6 months) in sunitinib-treated patients.

The study demonstrated a statistically significant benefit in PFS, OS, and ORR for patients randomised to nivolumab in combination with cabozantinib as compared to sunitinib. Efficacy results from the primary analysis (minimum follow-up 10.6 months; median follow-up 18.1 months) are shown in Table 15.

**Table 15: Efficacy results (CA2099ER)**

	<b>nivolumab + cabozantinib (n = 323)</b>	<b>sunitinib (n = 328)</b>
<b>Progression-free survival</b>		
Events	144 (44.6%)	191 (58.2%)
Hazard ratio <sup>a</sup>		0.51
95% CI		(0.41, 0.64)
p-value <sup>b, c</sup>		< 0.0001
Median (95% CI) <sup>d</sup>	16.59 (12.45, 24.94)	8.31 (6.97, 9.69)
<b>Overall survival</b>		
Events	67 (20.7%)	99 (30.2%)
Hazard ratio <sup>a</sup>		0.60
98.89% CI		(0.40, 0.89)
p-value <sup>b, c, e</sup>		0.0010
Median (95% CI)	N.E.	N.E. (22.6, N.E.)
Rate (95% CI)		
At 6 months	93.1 (89.7, 95.4)	86.2 (81.9, 89.5)
<b>Confirmed objective response (BICR)</b>		
	180 (55.7%)	89 (27.1%)
(95% CI) <sup>f</sup>	(50.1, 61.2)	(22.4, 32.3)
Difference in ORR (95% CI) <sup>g</sup>		28.6 (21.7, 35.6)
p-value <sup>h</sup>		< 0.0001
Complete response (CR)	26 (8.0%)	15 (4.6%)
Partial response (PR)	154 (47.7%)	74 (22.6%)
Stable disease (SD)	104 (32.2%)	138 (42.1%)
<b>Median duration of response<sup>d</sup></b>		
Months (range)	20.17 (17.31, N.E.)	11.47 (8.31, 18.43)
<b>Median time to response</b>		
Months (range)	2.83 (1.0-19.4)	4.17 (1.7-12.3)

<sup>a</sup> Stratified Cox proportional hazards model. Hazard ratio is nivolumab and cabozantinib over sunitinib.

<sup>b</sup> Log-rank test stratified by IMDC prognostic risk score (0, 1-2, 3-6), PD-L1 tumour expression (≥1% versus <1% or indeterminate) and region (US/Canada/W Europe/N Europe, ROW) as entered in the IRT.

<sup>c</sup> 2-sided p-values from stratified regular log-rank test.

<sup>d</sup> Based on Kaplan-Meier estimates.

<sup>e</sup> Boundary for statistical significance p-value <0.0111.

<sup>f</sup> CI based on the Clopper and Pearson method.

<sup>g</sup> Strata adjusted difference in objective response rate (nivolumab + cabozantinib - sunitinib) based on DerSimonian and Laird.

<sup>h</sup> 2-sided p-value from CMH test.

NE = non-estimable

The primary analysis of PFS included censoring for new anti-cancer treatment (Table 15). Results for PFS with and without censoring for new anti-cancer treatment were consistent.


PFS benefit was observed in the nivolumab in combination with cabozantinib arm vs. sunitinib regardless of the IMDC risk category. Median PFS for the favourable risk group was not reached for nivolumab in combination with cabozantinib, and was 12.81 months in the sunitinib arm (HR = 0.60; 95% CI: 0.37, 0.98). Median PFS for the intermediate risk group was 17.71 months for nivolumab in combination with cabozantinib and was 8.38 months in the sunitinib arm (HR = 0.54; 95% CI: 0.41,

0.73). Median PFS for the poor risk group was 12.29 months for nivolumab in combination with cabozantinib and was 4.21 months in the sunitinib arm (HR = 0.36; 95% CI: 0.23, 0.58).


PFS benefit was observed in the nivolumab in combination with cabozantinib arm vs. sunitinib regardless of tumour PD-L1 expression. Median PFS for tumour PD-L1 expression  $\geq 1\%$  was 13.08 months for nivolumab in combination with cabozantinib, and was 4.67 months in the sunitinib arm (HR = 0.45; 95% CI: 0.29, 0.68). For tumour PD-L1 expression  $< 1\%$ , the median PFS was 19.84 months for nivolumab in combination with cabozantinib, and 9.26 months in the sunitinib arm (HR = 0.50; 95% CI: 0.38, 0.65).

An updated PFS and OS analysis were performed when all patients had a minimum follow-up of 16.0 months and a median follow-up of 23.5 months (see Figures 9 and 10). The PFS hazard ratio was 0.52 (95% CI: 0.43, 0.64). The OS hazard ratio was 0.66 (95% CI: 0.50, 0.87). Updated efficacy data (PFS and OS) in subgroups for the IMDC risk categories and PD-L1 expression levels confirmed the original results. With the updated analysis, median PFS is reached for the favourable risk group.

**Figure 9: Kaplan-Meier curves of PFS (CA2099ER)**



**Figure 10: Kaplan-Meier curves of OS (CA2099ER)**



Number of subjects at risk

Nivolumab + cabozantinib											
323	308	295	283	269	255	220	147	84	40	10	0
Sunitinib											
328	295	272	254	236	217	189	118	62	22	4	0

—△— Nivolumab + cabozantinib (events: 86/323), median and 95% CI: NE

--○-- Sunitinib (events: 116/328), median and 95% CI: 29.47 (28.35, NE)

### *Gastric, gastro-oesophageal junction or oesophageal adenocarcinoma*

The safety and efficacy of nivolumab 240 mg every 2 weeks or 360 mg every 3 weeks in combination with chemotherapy (dose and schedule of nivolumab selected depending on the chemotherapy regimen used, see below) was evaluated in a phase 3, randomised, open-label study (CA209649). The study included adult patients (18 years or older) with previously untreated advanced or metastatic gastric, gastro-oesophageal junction (GEJ) or oesophageal adenocarcinoma, no prior systemic treatment (including HER2 inhibitors), and ECOG performance status score 0 or 1. Patients were enrolled regardless of their tumour cell PD-L1 status, and tumour cell PD-L1 expression was determined using the PD-L1 IHC 28-8 pharmDx assay. A retrospective re-scoring of a patient's tumour PD-L1 status using CPS was conducted using the PD-L1-stained tumour specimens used for randomisation. Patients with known HER2-positive tumours, who had baseline ECOG performance score  $\geq 2$ , untreated central nervous system metastases, or who had active, known, or suspected autoimmune disease, or medical conditions requiring systemic immunosuppression were excluded from the study. A total of 643 patients with HER2-undetermined status (40.3% of the study population) were included in the study. Randomisation was stratified by tumour cell PD-L1 status ( $\geq 1\%$  vs.  $< 1\%$  or indeterminate), region (Asia vs. US vs. rest of world), ECOG performance status (0 vs. 1), and chemotherapy regimen. Chemotherapy consisted of FOLFOX (fluorouracil, leucovorin and oxaliplatin) or CapeOX (capecitabine and oxaliplatin).

A total of 1581 patients were randomised to receive either nivolumab in combination with chemotherapy or chemotherapy. Of these, 955 patients had PD-L1 CPS  $\geq 5$ ; 473 in the nivolumab plus chemotherapy arm and 482 in the chemotherapy arm. Patients in the nivolumab plus chemotherapy arm received either nivolumab 240 mg by intravenous infusion over 30 minutes in combination with FOLFOX (oxaliplatin 85 mg/m<sup>2</sup>, leucovorin 400 mg/m<sup>2</sup> and fluorouracil 400 mg/m<sup>2</sup> intravenously on day 1 and fluorouracil 1200 mg/m<sup>2</sup> intravenously by continuous infusion over 24 hours daily or per local standard on days 1 and 2) every 2 weeks, or nivolumab 360 mg by intravenous infusion over 30 minutes in combination with CapeOX (oxaliplatin 130 mg/m<sup>2</sup> intravenously on day 1 and capecitabine 1000 mg/m<sup>2</sup> orally twice daily on days 1-14) every 3 weeks. Treatment continued until disease progression, unacceptable toxicity, or for up to 24 months for nivolumab only. In patients who received nivolumab plus chemotherapy and in whom chemotherapy was discontinued, nivolumab monotherapy was allowed to be given at 240 mg every 2 weeks, 360 mg every 3 weeks or 480 mg every 4 weeks up to 24 months after treatment initiation. Tumour assessments were performed every 6 weeks up to and including week 48, then every 12 weeks thereafter.

Baseline characteristics were generally balanced across treatment groups. In patients with PD-L1 CPS  $\geq 5$ , the median age was 62 years (range: 18-90), 11% were  $\geq 75$  years of age, 71% were male, 25% were Asian and 69% were white. Baseline ECOG performance status was 0 (42%) or 1 (58%). Tumour locations were distributed as gastric (70%), GEJ (18%) and oesophagus (12%).

Primary efficacy outcome measures were PFS (by BICR) and OS assessed in patients with PD-L1 CPS  $\geq 5$  based on the PD-L1 IHC 28-8 pharmDX. Secondary endpoints per the pre-specified hierarchical testing were OS in patients with PD-L1 CPS  $\geq 1$  and in all randomised patients; further endpoints included ORR (BICR) in PD-L1 CPS  $\geq 5$  and all randomised patients. At the primary pre-specified analysis, with a minimum follow-up of 12.1 months, the study demonstrated a statistically significant improvement in OS and PFS in patients with PD-L1 CPS  $\geq 5$ . Median OS was 14.4 months (95% CI: 13.1, 16.2) for nivolumab in combination with chemotherapy vs. 11.1 months (95% CI: 10.0, 12.1) for chemotherapy (HR = 0.71; 98.4% CI: 0.59, 0.86; p-value <0.0001). Median PFS was 7.69 months (95% CI: 7.03, 9.17) for nivolumab in combination with chemotherapy vs. 6.05 months (95% CI: 5.55, 6.90) for chemotherapy (HR = 0.68; 98% CI: 0.56, 0.81; p-value <0.0001). The ORR was 60% (95% CI: 55, 65) for nivolumab in combination with chemotherapy vs. 45% (95% CI: 40, 50) for chemotherapy.

At an updated descriptive analysis with a minimum follow-up of 19.4 months, OS improvements were consistent with the primary analysis. Efficacy results are shown in Table 16 and Figures 11, and 12.

**Table 16 Efficacy results in patients with PD-L1 CPS  $\geq 5$  (CA209649)**

	<b>nivolumab + chemotherapy (n = 473)</b>		<b>chemotherapy (n = 482)</b>
Minimum follow-up 19.4 months <sup>a</sup>			
<b>Overall survival</b>			
Events	344 (73%)		397 (82%)
Hazard ratio (95% CI) <sup>b</sup>		0.69 (0.60, 0.81)	
Median (95% CI) (months) <sup>c</sup>	14.4 (13.1, 16.3)		11.1 (10.0, 12.1)
Rate (95% CI) at 12 months	57.3 (52.6, 61.6)		46.4 (41.8, 50.8)
<b>Progression-free survival<sup>d</sup></b>			
Events	342 (72.3%)		366 (75.9%)
Hazard ratio (CI) <sup>b</sup>		0.68 (0.59, 0.79)	
Median (95% CI) (months) <sup>c</sup>	8.31 (7.03, 9.26)		6.05 (5.55, 6.90)
Rate (95% CI) at 12 months	36.3 (31.7, 41.0)		21.9 (17.8, 26.1)
<b>Objective response rate, n<sup>d,e</sup></b>			
(95% CI)	227/378 (60%) (54.9, 65.0)		176/390 (45%) (40.1, 50.2)
Complete response	12.2%		6.7%
Partial response	47.9%		38.5%
<b>Duration of response<sup>d,e</sup></b>			

**Table 16 Efficacy results in patients with PD-L1 CPS  $\geq$  5 (CA209649)**

	<b>nivolumab + chemotherapy (n = 473)</b>	<b>chemotherapy (n = 482)</b>
Median (95% CI) (months) <sup>c</sup>	9.69 (8.25, 12.22)	6.97 (5.62, 7.85)

<sup>a</sup> Descriptive analysis based on data cut-off: 04-Jan-2021.


<sup>b</sup> Based on stratified long Cox proportional hazard model.

<sup>c</sup> Kaplan-Meier estimate.

<sup>d</sup> Confirmed by BICR.

<sup>e</sup> Based on patients with measurable disease at baseline.

**Figure 11: Kaplan-Meier curves of OS in patients with PD-L1 CPS  $\geq$  5 (CA209649)**



Number of subjects at risk

Nivolumab + chemotherapy

473 439 378 314 263 223 187 155 118 78 56 37 23 13 4 0

Chemotherapy


482 421 350 272 213 152 122 92 68 44 28 16 8 2 0 0

—△— Nivolumab + chemotherapy (events: 344/473), median and 95% CI: 14.42 (13.14, 16.26)

--○-- Chemotherapy (events: 397/482), median and 95% CI: 11.10 (10.02, 12.09)

Minimum follow-up of 19.4 months

**Figure 12: Kaplan-Meier curves of PFS in patients with PD-L1 CPS  $\geq 5$  (CA209649)**



Number of subjects at risk

Nivolumab + chemotherapy

473 386 259 186 143 115 88 67 47 31 20 11 4 1 0

Chemotherapy

482 328 202 114 81 58 46 30 20 16 12 7 3 0 0

—△— Nivolumab + chemotherapy (events: 342/473), median and 95% CI: 8.31 (7.03, 9.26)

--○-- Chemotherapy (events: 397/482), median and 95% CI: 6.05 (5.55, 6.90)

Minimum follow-up of 19.4 months

### *Advanced urothelial carcinoma*

#### Randomised open-label phase 3 study of nivolumab in combination with chemotherapy vs. chemotherapy (CA209901)

The safety and efficacy of nivolumab in combination with cisplatin and gemcitabine followed by nivolumab monotherapy were evaluated in a randomised open-label study CA209901 in cisplatin-eligible patients with unresectable or metastatic urothelial carcinoma. The study included subjects (18 years or older) with histological or cytological evidence of metastatic or surgically unresectable transitional cell carcinoma (TCC) of the urothelium involving the renal pelvis, ureter, bladder or urethra, who were eligible for cisplatin and gemcitabine. Minor histologic variants (< 50% overall) were acceptable (TCC must have been the dominant histology). All subjects were required to have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria. No prior systemic anti-cancer therapy for metastatic or surgically unresectable urothelial carcinoma was permitted. Prior neoadjuvant chemotherapy or prior adjuvant platinum-based chemotherapy following radical cystectomy were permitted as long as the disease recurrence took place  $\geq 12$  months from completion of therapy. Prior intravesical therapy was permitted if completed at least 4 weeks prior to initiation of study treatment. Radiation therapy (with or without chemotherapy)

with curative intent was permitted if treatment was completed  $\geq 12$  months before enrolment. Palliative radiotherapy was permitted as long as it was completed at least 2 weeks prior to therapy.

A total of 608 patients were randomised to receive either nivolumab in combination with cisplatin and gemcitabine (n=304) or cisplatin and gemcitabine (n=304). Randomisation was stratified by tumour PD-L1 status ( $\geq 1\%$  vs.  $< 1\%$  or indeterminate) and liver metastasis (yes vs. no). The median age was 65 years of age (range: 32 to 86) with 49% of patients  $\geq 65$  years of age and 11% of patients  $\geq 75$  years of age, 23% were Asian, 72% were White, 0.3% were Black; 77% were male, 23% were female. Baseline ECOG performance status was 0 (53%) or 1 (46%). Patients in the nivolumab in combination with cisplatin and gemcitabine arm were treated with nivolumab 360 mg every three weeks, in combination with cisplatin and gemcitabine for up to 6 cycles, after which patients received nivolumab monotherapy 480 mg every 4 weeks for a total of up to 24 months. Patients received gemcitabine dosed at 1000 mg/m<sup>2</sup> IV over 30-minutes on Days 1 and 8 of the 3 week treatment cycle and cisplatin dosed at 70 mg/m<sup>2</sup> IV over 30 to 120-minutes on Day 1 of the 3 week treatment cycle. A total of 92 patients (49 in the nivolumab in combination with cisplatin and gemcitabine arm and 43 in the cisplatin and gemcitabine arm) switched from cisplatin to carboplatin after at least one cycle of cisplatin.

The study demonstrated a statistically significant benefit in OS and PFS for patients randomised to nivolumab in combination with cisplatin and gemcitabine compared to cisplatin and gemcitabine alone. Efficacy results are presented in Table 17 and Figures 13 and 14.

**Table 17: Efficacy Results (CA209901)**


	<b>nivolumab and cisplatin-gemcitabine chemotherapy (n=304)</b>	<b>cisplatin- gemcitabine chemotherapy (n=304)</b>
<b>Overall Survival<sup>a</sup></b>		
Events	172 (56.6)	193 (63.5)
Median (months) (95% CI)	21.7 (18.6, 26.4)	18.9 (14.7, 22.4)
Hazard ratio (95% CI) <sup>b</sup>	0.78 (0.63, 0.96)	
p-value <sup>c</sup>	0.0171	
<b>Progression-free Survival<sup>a</sup></b>		
Events	211 (69.4)	191 (62.8)
Median (months) (95% CI)	7.92 (7.62, 9.49)	7.56 (6.05, 7.75)
Hazard ratio (95% CI) <sup>b</sup>	0.72 (0.59, 0.88)	
p-value <sup>c</sup>	0.0012	
<b>Objective Response Rate</b>		
Responders (95% CI)	175 (57.6) (51.8, 63.2)	131 (43.1) (37.5, 48.9)

<sup>a</sup> Based on Kaplan-Meier Estimates

<sup>b</sup> Stratified Cox proportional hazard model.

<sup>c</sup> 2 sided p-value from stratified log-rank test.

**Figure 13: Kaplan Meier curves of OS (CA209901)**




Number of subjects at risk

Nivolumab + gemcitabine-cisplatin chemotherapy																					
304	286	264	228	196	167	142	119	97	84	69	58	48	36	25	20	15	12	7	4	2	0
Gemcitabine-cisplatin chemotherapy																					
304	277	242	208	166	140	122	102	82	65	49	39	33	24	17	16	13	9	4	4	1	0

- ▲--- Nivolumab + gemcitabine-cisplatin chemotherapy (events: 172/304), median and 95% CI: 21.72 (18,63, 26.38)
- Gemcitabine-cisplatin chemotherapy (events: 193/304), median and 95% CI: 18.85 (14.72, 22.44)

Based on clinical data cut-off: 09-May-2023, minimum follow-up of 7.4 months

**Figure 14: Kaplan Meier curves of PFS (CA209901)**



Number of subjects at risk

Nivolumab + gemcitabine-cisplatin chemotherapy	304	253	179	116	82	65	57	49	41	36	31	26	19	14	11	10	10	6	5	1	0
Gemcitabine-cisplatin chemotherapy	304	223	119	63	35	25	17	12	12	10	9	8	6	5	2	1	1	0	0	0	0

- ▲--- Nivolumab + gemcitabine-cisplatin chemotherapy (events: 211/304), median and 95% CI: 7.92 (7.62, 9.49)
- Gemcitabine-cisplatin chemotherapy (events: 191/304), median and 95% CI: 7.56 (6.05, 7.75)

Based on clinical data cut-off: 09-May-2023, minimum follow-up of 7.4 months

The primary analysis of PFS included censoring for new anti-cancer treatment before disease progression (Table 16). Results for PFS with and without censoring for new anti-cancer treatment before disease progression were consistent.

Safety and efficacy in elderly patients

No overall differences in safety or efficacy were reported between elderly ( $\geq 65$  years) and younger patients ( $< 65$  years). Data from patients 75 years of age or older are too limited to draw conclusions on this population.

**5.2 Pharmacokinetic properties**

The pharmacokinetics (PK) of nivolumab is linear in the dose range of 0.1 to 10 mg/kg. The geometric mean clearance (CL), terminal half-life, and average exposure at steady state at 3 mg/kg every 2 weeks of nivolumab were 7.9 mL/h, 25.0 days, and 86.6  $\mu\text{g/mL}$ , respectively, based on a population PK analysis.

Nivolumab CL increased with increasing body weight. Body weight normalised dosing produced approximately uniform steady-state trough concentration over a wide range of body weights (34-162 kg).

The metabolic pathway of nivolumab has not been characterised. Nivolumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.

#### Special populations

A population PK analysis suggested no difference in CL of nivolumab based on age, gender, race, tumour type, tumour size, and hepatic impairment. Although ECOG status, baseline glomerular filtration rate (GFR), albumin, body weight, and mild hepatic impairment had an effect on nivolumab CL, the effect was not clinically meaningful.

#### Renal impairment

The effect of renal impairment on the CL of nivolumab was evaluated in patients with mild (GFR < 90 and  $\geq 60$  mL/min/1.73 m<sup>2</sup>; n = 379), moderate (GFR < 60 and  $\geq 30$  mL/min/1.73 m<sup>2</sup>; n = 179), or severe (GFR < 30 and  $\geq 15$  mL/min/1.73 m<sup>2</sup>; n = 2) renal impairment compared to patients with normal renal function (GFR  $\geq 90$  mL/min/1.73 m<sup>2</sup>; n = 342) in population PK analyses. No clinically important differences in the CL of nivolumab were found between patients with mild or moderate renal impairment and patients with normal renal function. Data from patients with severe renal impairment are too limited to draw conclusions on this population (see section 4.2).

#### Hepatic impairment

The effect of hepatic impairment on the CL of nivolumab was evaluated in patients with mild hepatic impairment (total bilirubin  $1.0 \times$  to  $1.5 \times$  ULN or AST > ULN as defined using the National Cancer Institute criteria of hepatic dysfunction; n = 92) compared to patients with normal hepatic function (total bilirubin and AST  $\leq$  ULN; n = 804) in the population PK analyses. No clinically important differences in the CL of nivolumab were found between patients with mild hepatic impairment and normal hepatic function. Nivolumab has not been studied in patients with moderate (total bilirubin >  $1.5 \times$  to  $3 \times$  ULN and any AST) or severe hepatic impairment (total bilirubin >  $3 \times$  ULN and any AST) (see section 4.2).

### **5.3 Preclinical safety data**

Blockade of PD-L1 signalling has been shown in murine models of pregnancy to disrupt tolerance to the foetus and to increase foetal loss. The effects of nivolumab on prenatal and postnatal development were evaluated in monkeys that received nivolumab twice weekly from the onset of organogenesis in the first trimester through delivery, at exposure levels either 8 or 35 times higher than those observed at the clinical dose of 3 mg/kg of nivolumab (based on AUC). There was a dose-dependent increase in foetal losses and increased neonatal mortality beginning in the third trimester.

The remaining offspring of nivolumab-treated females survived to scheduled termination, with no treatment-related clinical signs, alterations to normal development, organ-weight effects, or gross and microscopic pathology changes. Results for growth indices, as well as teratogenic, neurobehavioral, immunological, and clinical pathology parameters throughout the 6-month postnatal period were comparable to the control group. However, based on its mechanism of action, foetal exposure to nivolumab may increase the risk of developing immune-related disorders or altering the normal immune response and immune-related disorders have been reported in PD-1 knockout mice.

Fertility studies have not been performed with nivolumab.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Sodium citrate dihydrate  
Sodium chloride  
Mannitol (E421)  
Pentetic acid (diethylenetriaminepentaacetic acid)  
Polysorbate 80  
Sodium hydroxide (for pH adjustment)  
Hydrochloric acid (for pH adjustment)  
Water for injections

### **6.2 Incompatibilities**

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. OPDIVO should not be infused concomitantly in the same intravenous line with other medicinal products.

### **6.3 Shelf life**

#### Unopened vial

3 years.

#### After opening

From a microbiological point of view, once opened, the medicinal product should be prepared for infusion immediately.

#### After preparation of infusion

The prepared infusion solution may be stored under refrigeration conditions: 2°C to 8°C and protected from light for up to 7 days (a maximum of 8 hours of the total 7 days can be at 20°C-25°C and room light - the maximum 8-hour period under 20°C-25°C and room light conditions should be inclusive of the product administration period). The administration of the nivolumab infusion must be completed within 7 days of preparation.

### **6.4 Special precautions for storage**

Store in a refrigerator (2°C-8°C).

Do not freeze.

Store in the original package in order to protect from light.

For storage conditions after preparation of the infusion, see section 6.3.

### **6.5 Nature and contents of container**

4 mL of concentrate in a 10 mL vial (Type I glass) with a stopper (coated butyl rubber) and a dark blue flip-off seal (aluminium). Pack size of 1 vial.

10 mL of concentrate in a 10 mL vial (Type I glass) with a stopper (coated butyl rubber) and a grey flip-off seal (aluminium). Pack size of 1 vial.

12 mL of concentrate in a 12 mL vial (Type I glass) with a stopper (coated butyl rubber) and a blue flip-off seal (aluminium). Pack size of 1 vial.

Not all pack sizes may be marketed.

## 6.6 Special precautions for disposal and other handling

Preparation should be performed by trained personnel in accordance with good practices rules, especially with respect to asepsis.

### Preparation and administration

#### Calculating the dose

The prescribed dose for the patient is given in mg/kg. Based on this prescribed dose, calculate the total dose to be given. More than one vial of OPDIVO concentrate may be needed to give the total dose for the patient.

- The total nivolumab dose in mg = the patient's weight in kg × the prescribed dose in mg/kg.
- The volume of OPDIVO concentrate to prepare the dose (mL) = the total dose in mg, divided by 10 (the OPDIVO concentrate strength is 10 mg/mL).

#### Nivolumab in combination with chemotherapy

The prescribed dose for the patient is 360 mg or 240 mg given regardless of body weight.

#### Nivolumab in combination with cabozantinib

The prescribed dose for the patient is nivolumab 240 mg or 480 mg given regardless of body weight.

#### Preparing the infusion

Take care to ensure aseptic handling when you prepare the infusion.

OPDIVO can be used for intravenous administration either:

- without dilution, after transfer to an infusion container using an appropriate sterile syringe; or
- after diluting according to the following instructions:
  - the final infusion concentration should range between 1 and 10 mg/mL.
  - the total volume of infusion must not exceed 160 mL.

OPDIVO concentrate may be diluted with either:

- sodium chloride 9 mg/mL (0.9%) solution for injection; or
- 50 mg/mL (5%) glucose solution for injection.

#### STEP 1

- Inspect the OPDIVO concentrate for particulate matter or discoloration. Do not shake the vial. OPDIVO concentrate is a clear to opalescent, colourless to pale yellow liquid. Discard the vial if the solution is cloudy, is discolored, or contains particulate matter other than a few translucent-to-white particles.
- Withdraw the required volume of OPDIVO concentrate using an appropriate sterile syringe.

#### STEP 2

- Transfer the concentrate into a sterile, evacuated glass bottle or intravenous container (PVC or polyolefin).
- If applicable, dilute with the required volume of sodium chloride 9 mg/mL (0.9%) solution for injection or 50 mg/mL (5%) glucose solution for injection. For ease of preparation, the concentrate can also be transferred directly into a pre-filled bag containing the appropriate volume of sodium chloride 9 mg/mL (0.9%) solution for injection or 50 mg/mL (5%) glucose solution for injection.
- Gently mix the infusion by manual rotation. Do not shake.

#### Administration

OPDIVO infusion must not be administered as an intravenous push or bolus injection.

Administer the OPDIVO infusion intravenously over a period of 30 minutes.

OPDIVO infusion should not be infused at the same time in the same intravenous line with other agents. Use a separate infusion line for the infusion.

Use an infusion set and an in-line, sterile, non-pyrogenic, low protein binding filter (pore size of 0.2 µm to 1.2 µm).

OPDIVO infusion is compatible with PVC and polyolefin containers, glass bottles, PVC infusion sets and in-line filters with polyethersulfone membranes with pore sizes of 0.2 µm to 1.2 µm.

After administration of the nivolumab dose, flush the line with sodium chloride 9 mg/mL (0.9%) solution for injection or 50 mg/mL (5%) glucose solution for injection.

#### Disposal

Do not store any unused portion of the infusion solution for reuse. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

### **Marketing Authorisation Holder**

DKSH Malaysia Sdn Bhd  
B-11-01, The Ascent, Paradigm  
No.1, Jalan SS7/26A, Kelana Jaya  
47301 Petaling Jaya, Selangor, Malaysia.

### **Manufacturer**

Bristol-Myers Squibb Holdings Pharma, Ltd.  
Liability Company  
Road 686 Km 2.3  
Bo. Tierras Nuevas  
Manatí, Puerto Rico 00674  
USA

Vetter Pharma-Fertigung GmbH & Co. KG  
Mooswiesen 2  
88214 Ravensburg  
Germany

### **Batch releaser**

Swords Laboratories Unlimited Company t/a Bristol-Myers Squibb Cruiserath Biologics  
Cruiserath Road  
Mulhuddart, Dublin 15, Ireland

## **8. DATE OF REVISION OF THE TEXT**

April 2026